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Abstract: Patients with chronic obstructive pulmonary disease (COPD), asthma and interstitial
lung diseases (ILD) frequently suffer from cardiovascular comorbidities (CVC). Exercise training is
a cornerstone intervention for the management of these conditions, however recommendations
on tailoring programmes to patients suffering from respiratory diseases and CVC are scarce.
This systematic review aimed to identify the eligibility criteria used to select patients with COPD,
asthma or ILD and CVC to exercise programmes; assess the impact of exercise on cardiovascular
outcomes; and identify how exercise programmes were tailored to CVC. PubMed, Scopus, Web
of Science and Cochrane were searched. Three reviewers extracted the data and two reviewers
independently assessed the quality of studies with the Quality Assessment Tool for Quantitative
Studies. MetaXL 5.3 was used to calculate the individual and pooled effect sizes (ES). Most studies
(58.9%) excluded patients with both stable and unstable CVC. In total, 26/42 studies reported
cardiovascular outcomes. Resting heart rate was the most reported outcome measure (n = 13) and a
small statistically significant effect (ES = −0.23) of exercise training on resting heart rate of patients
with COPD was found. No specific adjustments to exercise prescription were described. Few studies
have included patients with CVC. There was a lack of tailoring of exercise programmes and limited
effects were found. Future studies should explore the effect of tailored exercise programmes on
relevant outcome measures in respiratory patients with CVC.
Keywords: exercise; chronic lung disease; chronic obstructive pulmonary disease; COPD; asthma;
interstitial lung disease; ILD; cardiovascular comorbidities; cardiovascular outcomes
1. Background
Chronic obstructive pulmonary disease (COPD), asthma and interstitial lung diseases (ILD) are
among the most representative chronic respiratory diseases in the world [1,2]. These diseases affect
over 1 billion people and have a significant impact on patients’ disability and quality of life (9.5% of
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the disability-adjusted life years in 2010 [3]), being a leading contributor to disease burden and one of
the top causes of death worldwide (over 3 million deaths in 2016) [2–4].
In recent years, the association between chronic respiratory diseases and cardiovascular diseases
has attracted huge interest in clinical research [5]. Cardiovascular diseases (e.g., arterial hypertension,
coronary artery disease, congestive heart failure, peripheral vascular disease and pulmonary
hypertension) are among the most prevalent and impactful comorbidities in patients with COPD
(13%–68% of population), asthma (3%–25% of population) and ILD (8%–86% of population) [6–13].
Namely, they are responsible for further impairing patients’ functional status and health-related
quality of life, increasing the risk of hospitalization and mortality (hazard ratio 1.1–3.4 [14–17]), and
contributing to a higher economic and societal burden, and worse prognosis [7,9,10,12]. The need
to look beyond the lungs while treating these patients is, therefore, evident [18]. In this regard, a
comprehensive assessment and management of these cardiovascular comorbidities with tailored
interventions has been recommended [7,12,19,20].
Exercise training is a cornerstone intervention in both pulmonary and cardiac rehabilitation [21,22].
It relieves symptoms and improves functionality, exercise tolerance and health-related quality of
life in patients with chronic respiratory and cardiovascular diseases [21,22], and therefore might
be a promising intervention for the management of patients with these co-occurring conditions.
Nevertheless, studies have shown that these effects are usually reduced in patients suffering from
chronic respiratory diseases with accompanying cardiovascular comorbidities compared to those
without cardiovascular comorbidities [7,19,23]. Moreover, recommendations on how to adjust exercise
programmes to co-existing cardiovascular conditions in COPD, asthma and ILD are scarce.
Therefore, in order to inform evidence-based statements, this systematic review aimed to:
(i) identify the eligibility criteria in terms of cardiovascular disease that have been used to refer patients
with COPD, asthma and ILD for studies investigating the effectiveness of exercise programmes of
at least 3 months; (ii) assess the impact of at least 3 months of exercise training on cardiovascular
outcomes in these patients; and (iii) identify how the exercise programmes have been tailored to
patients’ cardiovascular comorbidities.
2. Methods
2.1. Search Strategy
This systematic review was reported according to the Preferred Reporting Items for Systematic
reviews and Meta-analyses (PRISMA) guidelines [24] and was conducted in two phases. Phase 1
identified the eligibility criteria that have been used to select patients with cardiovascular comorbidities
in clinical trials investigating the effectiveness of exercise programmes. Phase 2 assessed the impact of
exercise training on cardiovascular outcomes, and identified how the exercise programmes have been
tailored to patients’ cardiovascular comorbidities.
A systematic literature search was performed in May 2019 on the following electronic databases:
PubMed, Scopus, Web of Science and Cochrane. The search terms were limited to titles, abstracts and
keywords/MeSH terms. The full search strategy is presented in Appendix A.
2.2. Eligibility Criteria and Study Selection
For phase 1, studies were included if they (i) studied adult patients with stable COPD, asthma
and/or ILD (i.e., 4 weeks without exacerbations); (ii) implemented at least 12 weeks of exercise training
(i.e., endurance and/or strength training) as an intervention [25]; (iii) implemented at least 2 directly
supervised exercise sessions per week [26]; (iv) were original prospective quantitative studies; and (v)
were written in Portuguese, English, French, Dutch or Spanish languages. Retrospective studies, case
studies, case series, abstracts and studies involving alternative modalities of exercise (e.g., yoga, tai chi,
qigong) were excluded. After removing duplicates, three reviewers (AM, KQ and AO) assessed all the
potential studies identified. Studies were selected based on their titles and abstracts. When the title
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and abstract were potentially relevant to the purpose of the review, the full text was read carefully to
decide on its inclusion. A fourth reviewer (CB) was consulted to solve any disagreements.
For phase 2, studies included in phase 1 that specified the prevalence of cardiovascular
comorbidities (i.e., any cardiovascular condition co-existing with the respiratory disease, identified by
doing an objective patients’ assessment, checking their medical records or ask patients to self-report
their comorbidities) in the baseline characteristics of the population under study and/or reported at
least one cardiovascular outcome (i.e., heart rate, systolic and diastolic blood pressure, flow-mediated
dilation, pulse-wave velocity, intima thickness of arteria carotid, cardiac function and structure, heart
rate variability, ECG analysis and blood lipid profile) were included.
2.3. Quality Assessment and Data Extraction
Two reviewers (KQ and AO) independently assessed the quality of the studies included in phase
2 with the Quality Assessment Tool for Quantitative Studies, developed by the Effective Public Health
Practice Project, Canada [27]. This tool assesses six domains of methodological quality: (i) selection bias;
(ii) study design; (iii) confounders; (iv) blinding; (v) data collection methods; and (vi) withdrawals and
dropouts [27]. Each domain is rated as “strong”, “moderate” or “weak”, according to a standardized
guide, and the overall rating of the study is determined based on the total number of “strong” and
“weak” scores [27].
In phase 1, data regarding the eligibility criteria (i.e., inclusion and exclusion criteria) used to select
patients for the study were extracted from all included studies. Afterwards, all conditions that would
preclude patients’ participation in the exercise programmes, reported either as reasons for inclusion
(e.g., absence of severe cardiovascular disease) or exclusion (e.g., presence of severe cardiovascular
disease) of these patients, were compiled and reported as exclusion criteria. Additionally, data from
the studies included in phase 2 were extracted in a predesigned structured table format comprising the
following topics: study (first author, year of publication, country); study design; population (number of
participants, diagnosis, age, gender, forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC),
diffusing capacity for carbon monoxide (DLCO)); intervention (type and intensity of intervention);
duration and frequency (duration of the intervention, duration and frequency of sessions); outcome
and outcome measure; and results. For the scope of this review, only cardiovascular outcomes and
outcome measures were considered.
2.4. Data Analysis and Synthesis
Inter-rater agreement analysis using Cohen’s kappa was used to explore the consistency of the
quality assessment performed by the two reviewers. The value of Cohen’s kappa ranges from 0 to 1
and can be interpreted as slight (≤0.2), fair (0.21–0.4), moderate (0.41–0.6), substantial (0.61–0.8), or
almost perfect (≥0.81) agreement [28]. The statistical analysis was performed using IBM SPSS 24.0
(IBM, Armonk, New York, NY, USA).
Whenever possible, effect sizes (ES) were calculated and a meta-analysis was performed. ES were
calculated as Cohens’ d based on the Pre/Post means and standard deviations or mean differences and
standard deviations, according to the formula of Morris [29], and interpreted as small (≥0.2), medium
(≥0.5) or large (≥0.8) [30]. Meta-analysis was performed on MetaXL 5.3. Pooled effect estimates were
calculated with the inverse variance technique assuming a fixed-effects model. The input data were the
Cohen’s d value of each study and the respective standard error. The output was the pooled Cohen’s d
value and corresponding confidence intervals. Homogeneity among the studies was evaluated using
Cochran’s Q test and the I2 statistic.
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3. Results
3.1. Study Selection
The literature search provided a total of 50.970 records. After duplicates removal, 29.756 records
were screened for relevant content through title and abstract and 29.248 were excluded. The full text of
508 potentially relevant articles was assessed. From these, 180 articles were included in phase 1 and 42
in phase 2 (Figure 1).
Figure 1. PRISMA flowchart of the included studies.
3.2. Phase 1: Criteria Used to Exclude Patients with Cardiovascular Comorbidities from Exercise Programmes
The 180 studies included were conducted between 1987 and 2019. In total, 156 studies included
patients with COPD [23,31–185], 15 studies included patients with asthma [46,52,63,78,185–195] and
16 studies included patients with ILD [87,185,196–209].
Forty-four different exclusion criteria were found in studies with patients with COPD (Figure 2).
From these, exercise-limiting conditions [34,36,40,53,60,61,89,92,104,114,125,134,135,138,148,157,166–
170,173,174,179,181,183,184] (n = 27; 17.3%) was the most reported exclusion criterion, followed
by general cardiovascular disease [32,39,44,70,74,75,94,100,103,107,109,112,130,152,153,160,164,171]
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(n = 18; 11.5%) and unstable cardiovascular disease [38,47,53,65,66,98,99,101,108,116–119,133,137,146,
147,180] (n = 18; 11.5%). Thirty-four (21.8%) of the studies [23,48,50,55,63,67,69,73,77–80,83,84,86,88,
91,95,97,110,111,115,122,126,127,132,142,149,150,155,161,165,175,185] did not report any information
regarding the eligibility criteria for cardiovascular comorbidities.
Figure 2. Exclusion criteria reported in studies with patients with chronic obstructive pulmonary
disease (COPD) (n = 156 studies).
In studies including patients with asthma, 10 different exclusion criteria were found (Figure 3).
General cardiovascular disease [186,191,192] (n = 3; 20.0%) was the most reported criterion, followed
by contraindications to exercise training and/or testing [194,195] (n = 2; 13.3%). Seven (46.7%)
studies [63,78,185,187,189,190,193] did not report information about exclusion criteria.
Studies in patients with ILD reported 10 different exclusion criteria (Figure 4). From these,
unstable cardiovascular disease [198,199,202,203,208,209] (n = 6; 37.5%) was the most reported
criterion, followed by contraindications to exercise training and/or testing (e.g., unstable angina,
recent myocardial infarction or cerebrovascular accident) [201,204,207] (n = 3; 18.8%). Four (25.0%)
studies [185,197,205,206] did not report any information about exclusion criteria.
In general, 22.8% of the studies [23,48,50,55,63,67,69,73,77–80,83,84,86,88,91,95,97,110,111,
115,122,126,127,132,142,149,150,155,161,165,175,185,187,189,190,193,197,205,206] did not report
information about the eligibility criteria, 18.3% of the studies [33,42,54,65,66,72,82,96,98,99,101,
108,116–119,128,137,141,143,145,146,180,182,194,195,200–203,207–209] only excluded patients with
acute or unstable cardiovascular comorbidities that contraindicated exercise training, and 58.9%
of the studies [31,32,34–41,43–47,49,51–53,56–62,64,68,70,71,74–76,81,85,87,89,90,92–94,100,102–
107,109,112–114,120,121,123–125,129–131,133–136,138–140,144,147,148,151–154,156–160,162–164,
166–174,176–179,181,183,184,186,188,191,192,196,198,199,204] excluded both stable and unstable
cardiovascular comorbidities.
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Figure 3. Exclusion criteria reported in studies with patients with asthma (n = 15 studies).
Figure 4. Exclusion criteria reported in studies with patients with interstitial lung diseases (ILD)
(n = 16 studies).
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3.3. Phase 2: Impact of Exercise Training on Cardiovascular Outcomes and Design of the Exercise Programmes
3.3.1. Quality Assessment
Results of the methodological quality assessment are presented in Table 1. Most of the studies
(n = 24; 57.1%) were of weak quality. The agreement between the two reviewers was substantial
(k = 0.72; 95%CI = 0.53–0.91; p < 0.001; percentage of agreement = 85.7%).
3.3.2. Study Characteristics
Characteristics of the included studies are shown in Tables 2–4. From the 42 included studies,
32 studies included patients with COPD [33,37,42–44,48,49,53–55,57,59,68,80,85,90,101,104,106–108,
120,121,123,124,128,129,136,146,147,151,167], two studies included patients with asthma [186,189] and
eight studies included patients with ILD [196,198,201–203,207–209]. Most studies were randomized
controlled trials (n = 24; 57.1%) [37,43,44,49,53,80,85,120,121,123,124,129,146,147,151,167,186,189,196,
198,202,207–209].
In total, 1704 patients (65.2% male; data gathered from 34 studies) with a weighted mean age of
65.4 years old and a mean FEV1 of 53.7% of predicted (data gathered from 36 studies) were enrolled in
the included studies.
Only 13 studies in patients with COPD [33,42–44,48,54,55,59,68,85,101,151,167] and six studies
in patients with ILD [196,198,203,207–209] specified the presence of patients with cardiovascular
comorbidities on the population’s baseline characteristics. No studies reporting to include
patients with cardiovascular comorbidities were found in asthma. Studies in patients with COPD
included patients suffering from arterial hypertension [33,42–44,48,54,68,85,151] (nine studies; 314
patients), cardiovascular diseases [43,44,48,55,59,85,101,151,167] (nine studies; 247 patients), circulatory
problems [42–44,85] (four studies; 84 patients), coronary heart disease [42] (one study; 54 patients),
congestive heart failure [33,54] (two studies; 10 patients), dyslipidaemia [33,54] (two studies; 11
patients) and ischemic cardiomyopathy [33] (one study; three patients). Studies in patients with ILD
included patients suffering from arterial hypertension [196,203,207–209] (five studies; 49 patients),
coronary heart disease [207–209] (three studies; 21 patients), congestive heart failure [203] (one study;
two patients), pulmonary hypertension [207–209] (three studies; 15 patients) and history of heart
disease [198] (one study; one patient). From these, only three studies [196,207,209] conducted in
patients with ILD reported cardiovascular outcomes and outcome measures.
Nineteen studies in patients with COPD [37,49,53,57,80,90,104,106–108,120,121,123,124,128,129,
136,146,147], two studies in asthma [186,189] and five studies in ILD [196,201,202,207,209] reported
cardiovascular outcomes and outcome measures. Studies conducted in patients with COPD presented
a large variety of outcome measures, while studies conducted in patients with asthma were mainly
focused on blood lipid profile [187,190] (n = 2) and studies in patients with ILD reported mainly
resting heart rate [196,201,209] (n = 3) and blood pressure [196,207,209] (n = 3). The most reported
outcome measure was resting heart rate [37,57,90,106,107,121,123,124,129,136,196,201,209] (n = 13;
ES = [−0.63; 0.11]).
J. Clin. Med. 2019, 8, 1458 8 of 46
Table 1. Quality assessment of the studies included in phase 2 (n = 42) with the Quality Assessment Tool for Quantitative Studies.
Study Selection Bias Study Design Confounders Blinding Data CollectionMethod
Withdrawals and
Drop-Outs Global Rating
Cochrane et al., 1990 3 1 1 3 1 3 3
Berry et al., 1999 2 2 3 3 1 1 3
Foy et al., 2001 3 1 3 3 1 1 3
Berry et al., 2003 2 1 1 2 1 1 1
Panton et al., 2004 2 1 3 3 1 1 3
Marquis et al., 2008 2 1 3 1 1 3 3
Averna et al., 2009 3 1 1 3 1 1 2
Berry et al., 2010 3 1 1 2 1 1 2
Rejbi et al., 2010 2 1 2 3 1 1 2
Camillo et al., 2011 2 1 1 3 1 1 2
Lan et al., 2011 3 2 2 3 1 3 3
Corhay et al., 2012 3 2 3 2 1 2 3
Georgiopoulou et al., 2012 2 2 NA 3 1 1 2
Lan et al., 2013 2 2 NA 3 1 3 3
Cheng et al., 2014 3 2 NA 3 1 3 3
Gaunaurd et al., 2014 3 1 1 3 1 1 3
Vainshelboim et al., 2014 3 1 1 3 1 1 3
Borghi-Silva et al., 2015 2 1 1 2 1 1 1
Campos et al., 2015 2 2 NA 3 1 1 2
Leite et al., 2015 2 1 1 3 1 3 3
Marcellis et al., 2015 2 2 NA 3 1 2 2
Mkacher et al., 2015 2 1 1 3 1 1 2
Spielmanns et al., 2015 3 1 1 2 1 3 3
Vainshelboim et al., 2015 2 1 1 3 1 1 2
Boström et al., 2016 3 1 1 2 1 1 2
Cardoso et al., 2016 2 1 3 3 1 1 3
El-Kader et al., 2016 3 1 1 3 1 1 3
Engel et al., 2016 3 1 1 1 1 1 2
Boeselt et al., 2017 3 1 1 3 1 2 3
Kanao et al., 2017 3 2 NA 3 1 1 3
Pacheco et al., 2017 2 3 NA 3 1 1 3
Papp et al., 2017 3 1 3 3 1 2 3
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Table 1. Cont.
Study Selection Bias Study Design Confounders Blinding Data CollectionMethod
Withdrawals and
Drop-Outs Global Rating
Vainshelboim et al., 2017 2 1 1 3 1 1 2
Vasilopoulou et al., 2017 3 1 3 3 1 1 3
Lan et al., 2018 3 2 NA 3 1 1 3
Moezy et al., 2018 3 1 1 3 1 1 3
Naz et al., 2018a 2 2 NA 3 1 1 2
Naz et al., 2018b 3 1 1 3 1 1 3
Silva et al., 2018 2 1 1 3 1 1 2
Charikiopoulou et al., 2019 2 2 3 3 1 1 3
Mekki et al., 2019 2 1 1 2 1 2 2
Silva et al., 2019 2 1 1 3 1 1 2
Legend: 1 = strong quality; 2 = moderate quality; 3 = weak quality; NA, not applicable.
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Table 2. Characteristics of the studies in patients with COPD included in phase 2 (i.e., studies that specified the prevalence of cardiovascular comorbidities in the
baseline characteristics of the population under study and/or reported at least one cardiovascular outcome) (n = 32).
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Berry et al., 1999
United States of
America
Non-controlled study
151 patients with COPD
Mild disease group: 99 (54♂;
67.4 ± 6.1 years; FEV1 68.0 ±
1.2%pred)
Arterial hypertension: n = 44
Circulatory problems: n = 14
Coronary heart disease: n = 34
Moderate disease group: 36
(22♂;
68.3 ± 6.2 years; FEV1 41.9 ±
0.7%pred)
Arterial hypertension: n = 16
Circulatory problems: n = 5
Coronary heart disease: n = 12
Severe disease group: 16 (10♂;
66.1 ± 5.6 years; FEV1 30.1 ±
0.9%pred)
Arterial hypertension: n = 7
Circulatory problems: n = 2
Coronary heart disease: n = 8
All groups: Aerobic
and strength training
Dyspnoea 3–4 in the
mBorg
All groups:
12 weeks
3 sessions/week
1 h/session
Foy et al., 2001
United States of
America
Randomized controlled
trial
140 patients with COPD
Short-term intervention group:
70 (39♂;
66.9 ± 5.9 years; FEV1 59.1 ±
17.2%pred)
Arterial hypertension: n = 29
Circulatory problems: n = 14
Cardiovascular disease: n = 27
Long-term intervention group:
70 (39♂;
68.4 ± 6.0 years; FEV1 57.6 ±
18.4%pred)
Arterial hypertension: n = 32
Circulatory problems: n = 9
Cardiovascular disease: n = 24
All groups:
Aerobic and strength
training
Dyspnoea 3–4 in the
mBorg
3 sessions/week
55–65 min/session
Short-term
intervention group:
12 weeks
Long-term
intervention group:
72 weeks
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Berry et al., 2003
United States of
America
Randomized controlled
trial
140 patients with COPD
Short-term intervention group:
70 (39♂;
66.9, 95%CI (65.5; 68.3) years;
FEV1 59.1, 95%CI (55.0;
63.2)%pred)
Arterial hypertension: n = 29
Circulatory problems: n = 14
Cardiovascular disease: n = 27
Long-term intervention group:
70 (39♂;
68.4, 95%CI (67.0; 69.8) years;
FEV1 57.6, 95%CI (53.2;
62.0)%pred)
Arterial hypertension: n = 32
Circulatory problems: n = 9
Cardiovascular disease: n = 24
All groups:
Aerobic and strength
training
Dyspnoea 3–4 in the
mBorg
3 sessions/week
1 h/session
Short-term
intervention group 1:
3 months
Long-term
intervention group:
18 months
Panton et al., 2004
United States of
America
Non-randomized
controlled trial
17 patients with COPD
Aerobic training group: 8 (2♂;
63.0 ± 8.0 years; FEV1 39.5 ±
31.9%pred)
Aerobic+strength training
group: 9 (6♂;
61.0 ± 7.0 years; FEV1 41.9 ±
16.0%pred)
Aerobic training
group: Aerobic
training
50%–70% of HR
reserve
Aerobic+strength
training group:
Aerobic and strength
training
50%–70% of HR
reserve
12 weeks
Aerobic training
group: 2
sessions/week
60 min/session
Aerobic + strength
training group: 4
sessions/week (2 of
each training)
45–60 min/session
Rate pressure product
Aerobic training group: Pre
177.0 ± 29.0 vs. Post 186.0 ±
30.0, p > 0.05
ES = 0.31
Aerobic+strength training
group: Pre 195.0 ± 35.0 vs.
Post 199.0 ± 35.0, p > 0.05
ES = 0.11
Total blood cholesterol
(mg/dl)
Aerobic training group: Pre
217.0 ± 46.0 vs. Post 217.0 ±
46.0, p > 0.05
ES = 0.00
Aerobic+strength training
group: Pre 201.0 ± 34.0 vs.
Post 193.0 ± 23.0, p > 0.05
ES = −0.28
Cholesterol – HDL (mg/dl)
Aerobic training group: Pre
62.0 ± 21.0 vs. Post 62.0 ±
20.0, p > 0.05
ES = 0.00
Aerobic+strength training
group: Pre 55.0 ± 16.0 vs.
Post 53.0 ± 12.0, p > 0.05
ES = −0.14
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Cholesterol – LDL (mg/dl)
Aerobic training group: Pre
129.0 ± 34.0 vs. Post 132.0 ±
35.0, p > 0.05
ES = 0.09
Aerobic+strength training
group: Pre 122.0 ± 21.0 vs.
Post 118.0 ± 15.0, p > 0.05
ES = −0.22
Cholesterol – Triglycerides
(mg/dl)
Aerobic training group: Pre
151.0 ± 65.0 vs. Post 185.0 ±
87.0, p < 0.05
ES = 0.44
Aerobic+strength training
group: Pre 141.0 ± 132.0 vs.
Post 135.0 ± 73.0, p > 0.05
ES = −0.06
Total cholesterol/HDL ratio
Aerobic training group: Pre
3.8 ± 1.1 vs. Post 3.9 ± 1.1,
p > 0.05
ES = 0.09
Aerobic+strength training
group: Pre 3.8 ± 0.8 vs.
Post 3.8 ± 0.8, p > 0.05
ES = 0.00
Marquis et al., 2008
Canada
Randomized controlled
trial
16 patients with COPD
Irbesartan+exercise group: 10
(7♂;
67.0 ± 7.0 years; FEV1 50.0 ±
19.0%pred; FVC 63.0 ±
16.0%pred; DLCO 80.0 ±
19.0%pred)
Placebo+exercise group: 6 (1♂;
72.0 ± 5.0 years; FEV1 39.0 ±
9.0%pred; FVC 63.0 ±
15.0%pred; DLCO 63.0 ±
18.0%pred)
All groups:
Aerobic training
80% of WRmax
All groups:
12 weeks
3 sessions/week
30 min/session
Systolic blood pressure at
rest (mmHg)
Irbesartan+exercise group:
Pre 151.0 ± 19.0 vs. Post
131.0 ± 18.0, p < 0.05
ES = −1.08
Placebo+exercise group:
Pre 140.0 ± 15.0 vs. Post
136.0 ± 15.0, p > 0.05
ES = −0.27
Mean systolic blood
pressure during 24 h
(mmHg)
Irbesartan+exercise group:
Pre 135.0 ± 9.0 vs. Post
126.0 ± 12.0, p < 0.01
ES = −0.85
Placebo+exercise group:
Pre 130.0 ± 14.0 vs. Post
128.0 ± 8.0, p > 0.05
ES = −0.18
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Mean systolic blood
pressure at daytime
(mmHg)
Irbesartan+exercise group:
Pre 139.0 ± 11.0 vs. Post
129.0 ± 15.0, p < 0.01
ES = −0.76
Placebo+exercise group:
Pre 130.0 ± 14.0 vs. Post
131.0 ± 8.0, p > 0.05
ES = 0.09
Mean systolic blood
pressure at nighttime
(mmHg)
Irbesartan+exercise group:
Pre 125.0 ± 8.0 vs. Post
121.0 ± 10.0, p > 0.05
ES = −0.44
Placebo+exercise group:
Pre 128.0 ± 16.0 vs. Post
121.0 ± 9.0, p > 005
ES = −0.54
Diastolic blood pressure at
rest (mmHg)
Irbesartan+exercise group:
Pre 78.0 ± 8.0 vs. Post 71.0
± 10.0, p < 0.05
ES = −0.77
Placebo+exercise group:
Pre 72.0 ± 8.0 vs. Post 68.0
± 10.0, p > 0.05
ES = −0.44
Mean diastolic blood
pressure during 24 h
(mmHg)
Irbesartan+exercise group:
Pre 76.0 ± 9.0 vs. Post 72.0
± 8.0, p < 0.05
ES = −0.47
Placebo+exercise group:
Pre 70.0 ± 3.0 vs. Post 70.0
± 8.0, p > 0.05
ES = 0.00
Mean diastolic blood
pressure at daytime
(mmHg)
Irbesartan+exercise group:
Pre 80.0 ± 11.0 vs. Post 74.0
± 10.0, p < 0.05
ES = −0.84
Placebo+exercise group:
Pre 71.0 ± 2.0 vs. Post 72.0
± 7.0, p > 0.05
ES = 0.19
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Mean diastolic blood
pressure at nighttime
(mmHg)
Irbesartan+exercise group:
Pre 68.0 ± 6.0 vs. Post 67.0
± 7.0, p > 0.05
ES = −0.15
Placebo+exercise group:
Pre 66.0 ± 6.0 vs. Post 65.0
± 8.0, p > 0.05
ES = −0.14
Standard deviation of all
NN intervals (ms)
Irbesartan+exercise group:
Pre 102.0 ± 28.0 vs. Post
144.0 ± 36.0, p > 0.05
ES = 1.30
Placebo+exercise group:
Pre 121.0 ± 27.0 vs. Post
113.0 ± 38.0, p > 0.05
ES = −0.24
Adjacent normal-to-normal
(NN) intervals differing by
more than 50 ms (%)
Irbesartan+exercise group:
Pre 9.0 ± 9.0 vs. Post 9.0 ±
8.0, p > 0.05
ES = 0.00
Placebo+exercise group:
Pre 10.0 ± 9.0 vs. Post 10.0
± 8.0, p > 0.05
ES = 0.00
Square root of the mean
squared differences of
successive NN intervals
(ms)
Irbesartan+exercise group:
Pre 30.0 ± 12.0 vs. Post 29.0
± 11.0, p > 0.05
ES = −0.09
Placebo+exercise group:
Pre 31.0 ± 11.0 vs. Post 30.0
± 10.0, p > 0.05
ES = −0.10
Very low frequency (ms)
Irbesartan+exercise group:
Pre 3.3 ± 0.2 vs. Post 3.3 ±
0.2, p > 0.05
ES = 0.00
Placebo+exercise group:
Pre 3.1 ± 0.2 vs. Post 3.1 ±
0.5, p > 0.05
ES = 0.07
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Low frequency (ms)
Irbesartan+exercise group:
Pre 2.9 ± 0.3 vs. Post 2.9 ±
0.3, p > 0.05
ES = −0.03
Placebo+exercise group:
Pre 2.8 ± 0.4 vs. Post 2.8 ±
0.4, p > 0.05
ES = 0.02
High frequency (ms)
Irbesartan+exercise group:
Pre 2.4 ± 0.3 vs. Post 2.4 ±
0.4, p > 0.05
ES = −0.03
Placebo+exercise group:
Pre 2.4 ± 0.4 vs. Post 2.4 ±
0.5, p > 0.05
ES = −0.12
Low frequency/High
frequency ratio
Irbesartan+exercise group:
Pre 3.0 ± 1.3 vs. Post 3.1 ±
1.3, p > 0.05
ES = 0.08
Placebo+exercise group:
Pre 2.1 ± 1.0 vs. Post 2.4 ±
1.0, p > 0.05
ES = 0.27
Averna et al., 2009
Italy
Randomized controlled
trial
56 patients with COPD (29♂;
69.0 ± 5.0 years; FEV1 82.0 ±
16.6%pred; FVC 91.0 ±
17.4%pred)
Aerobic and strength
training
40%–50% of HR
reserve
50% of 1 RM
12 weeks
3 sessions/week
60 min/session
HR at rest (bpm)
Pre 65.0 ± 10.0 vs. Post 65.0
± 9.0, p = 0.64
ES = 0.00
Systolic blood pressure at
rest (mmHg)
Pre 137.0 ± 12.0 vs. Post
131.0 ± 12.0, p = 0.001
ES = −0.70
Diastolic blood pressure at
rest (mmHg)
Pre 84.0 ± 6.0 vs. Post 80.0
± 7.0, p = 0.001
ES = −0.61
Berry et al., 2010
United States of
America
Randomized controlled
trial
89 patients with COPD (48♂;
66.0 ± 10.0 years; FEV1 53.0 ±
18.5%pred)
Arterial hypertension: n = 47
Circulatory problems: n = 17
Cardiovascular disease: n = 39
Aerobic and strength
training
Dyspnoea 3–5 in the
mBorg
12 weeks
3 sessions/week
1 h/session
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Rejbi et al., 2010
Tunisia
Non-randomized
controlled trial
26 patients with COPD (61.0 ±
4.0 years; FEV1 48.9 ±
11.3%pred; FVC 58.8 ±
9.8%pred)
Pulmonary
rehabilitation
HR of the gas
exchange threshold
3 months
3 sessions/week
45 min/session
HR at rest (bpm)
Pre 75.6 ± 13.9 vs. Post 76.5
± 14.0, p > 0.05
ES = 0.06
Camillo et al., 2011
Brazil
Randomized controlled
trial
40 patients with COPD
High-intensity group: 20 (10♂;
67.0 ± 7.0 years; FEV1 40.0 ±
13.0%pred)
Low-intensity group: 20 (11♂;
65.0 ± 10.0 years; FEV1 39.0 ±
14.0%pred)
High-intensity group:
Aerobic and strength
training
60% of WRmax
75% of average
walking speed in the
6MWT
70% of 1RM
Low-intensity group:
Strength training
All groups:
12 weeks
3 sessions/week
1 h/session
Standard deviation of N-N
intervals (ms)
High-intensity group: Pre
29.0 ± 15.0 vs. Post 36.0 ±
19.0, p < 0.05
ES = 0.41
Low-intensity group: Pre
25.0 ± 12.0 vs. Post 22.0 ±
10.0, p > 0.05
ES = −0.27
Square root of the mean
squared difference of the
successive N-N intervals
(ms)
High-intensity group: Pre
22.0 ± 14.0 vs. Post 28.0 ±
22.0, p < 0.05
ES = 0.33
Low-intensity group: Pre
22.0 ± 22.0 vs. Post 19.0 ±
14.0, p > 0.05
ES = −0.16
Low frequency in supine
(%)
High-intensity group: Pre
44.0 ± 15.0 vs. Post 42.0 ±
24.0, p > 0.05
ES = −0.10
Low-intensity group: Pre
48.0 ± 19.0 vs. Post 43.0 ±
19.0, p > 0.05
ES = −0.26
Low frequency in
orthostatic (%)
High-intensity group: Pre
55.0 ± 21.0 vs. Post 50.0 ±
20.0, p > 0.05
ES = −0.24
Low-intensity group: Pre
58.0 ± 15.0 vs. Post 62.0 ±
20.0, p > 0.05
ES = 0.23
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
)
High frequency in supine
(%)
High-intensity group: Pre
56.0 ± 15.0 vs. Post 58.0 ±
24.0, p > 0.05
ES = 0.10
Low-intensity group: Pre
51.0 ± 19.0 vs. Post 56.0 ±
19.0, p > 0.05
ES = 0.26
High frequency in
orthostatic (%)
High-intensity group: Pre
44.0 ± 21.0 vs. Post 50.0 ±
20.0, p > 0.05
ES = 0.29
Low-intensity group: Pre
41.0 ± 15.0 vs. Post 37.0 ±
20.0, p > 0.05
ES = −0.23
Low frequency/High
frequency ratio in supine
High-intensity group: Pre
0.9 ± 0.8 vs. Post 1.3 ± 1.5, p
> 0.05
ES = 0.60
Low-intensity group: Pre
1.2 ± 0.9 vs. Post 1.1 ± 1.2, p
> 0.05
ES = −0.09
Low frequency/High
frequency ratio in
orthostatic
High-intensity group: Pre
2.3 ± 3.1 vs. Post 1.3 ± 0.9, p
> 0.05
ES = −0.44
Low-intensity group: Pre
1.7 ± 1.0 vs. Post 2.8 ± 2.8, p
> 0.05
ES = 0.52
Lan et al., 2011
Taiwan Non-controlled study
44 patients with COPD
Underweight group: 22 (21♂;
69.1 ± 12.0 years; FEV1 52.8 ±
17.1%pred; FVC 79.5 ±
21.4%pred)
Non-underweight group: 22
(21♂;
71.4 ± 7.5 years; FEV1 51.5 ±
13.3%pred; FVC 79.1 ±
15.1%pred)
All groups:
Pulmonary
rehabilitation
50%–75% of VO2peak
All groups:
12 weeks
2 sessions/week
40–50 min/session
HR at rest (bpm)
Underweight group: Pre
85.2 ± 13.0 vs. Post 83.1 ±
11.7, p = 0.315
ES = −0.17
Non-underweight group:
Pre 88.2 ± 11.6 vs. Post 86.0
± 10.8, p = 0.029
ES = −0.20
J. Clin. Med. 2019, 8, 1458 18 of 46
Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Corhay et al., 2012
Belgium Non-controlled study
140 patients with COPD
<65 years group: 69 (42♂;
57.6 ± 5.2 years; FEV1 38.1 ±
10.8%pred)
Cardiovascular disease: n = 19
65–74 years group: 50 (36♂;
69.5 ± 2.6 years; FEV1 39.5 ±
11.7%pred)
Cardiovascular disease: n = 23
≥75 years group: 21 (17♂;
77.4 ± 2.5 years; FEV1 39.9 ±
9.2%pred)
Cardiovascular disease: n = 14
All groups:
Pulmonary
rehabilitation
50%–80% of WRmax
60% of maximal
walking speed in the
6MWT
50% of 1RM
All groups:
6 months
2–3 sessions/week
2 h/session
Georgiopoulou et
al., 2012
Greece
Pre-Post study
45 patients with COPD (40♂;
66.5 ± 7.6 years; FEV1 45.7 ±
18.7%pred; FVC 78.3 ±
18.6%pred)
Pulmonary
rehabilitation
60%–80% of WRmax
12 weeks
3 sessions/week
40 min/session
HR at rest (bpm)
Pre 88.0 ± 10.7 vs. Post 83.3
± 10.5, p = 0.004
ES = −0.63
HR recovery (bpm)
Pre 16.2 ± 8.0 vs. Post 18.4
± 8.4, p = 0.01
ES = 0.27
Lan et al., 2013
Taiwan
Pre-Post study
26 patients with COPD (71.0 ±
10.7 years; FEV1 64.8 ±
23.0%pred; FVC 88.3 ±
34.5%pred)
Pulmonary
rehabilitation
75%–100% of
VO2max
12 weeks
2 sessions/week
40 min/session
HR (bpm)
Pre 134.5 ± 14.9 vs. Post
137.4 ± 19.9, p = 0.36
ES = 0.16
Mean blood pressure
(mmHg)
Pre 109.6 ± 15.7 vs. Post
110.3 ± 15.1, p = 0.72
ES = 0.05
Oxygen pulse (ml/beat)
Pre 9.2 ± 2.5 vs. Post 9.8 ±
2.7, p = 0.02
ES = 0.23
Cheng et al., 2014
Taiwan
Pre-Post study
64 patients with COPD (55♂;
70.1 ± 8.7 years; FEV1 44.9 ±
11.7%pred; FVC 78.2 ±
17.4%pred)
Pulmonary
rehabilitation
60%–100% of
VO2peak
12 weeks
2 sessions/week
50 min/session
HR at rest (bpm)
Pre 87.2 ± 12.7 vs. Post 83.9
± 13.5, p = 0.048
ES = −0.25
Oxygen pulse (ml/beat)
Pre 7.2 ± 1.9 vs. Post 7.9 ±
2.2, p = 0.005
ES = 0.34
Oxygen pulse (%)
Pre 76.8 ± 18.4 vs. Post 85.2
± 24.8, p = 0.003
ES = 0.38
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Standard deviation of N-N
At rest: Pre vs. Post, p <
0.05
At exercise: Pre vs. Post,
p < 0.05
Square root of the mean
sum of the squares of the
difference between adjacent
normal R-R intervals
At rest: Pre vs. Post,
p < 0.05
At exercise: Pre vs. Post,
p < 0.05
Low frequency
At rest: Pre vs. Post,
p < 0.05
At exercise: Pre vs. Post,
p < 0.05
High frequency
At rest: Pre vs. Post,
p < 0.05
At exercise: Pre vs. Post,
p < 0.05
Low frequency/High
frequency ratio
At rest: Pre vs. Post,
p < 0.05
At exercise: Pre vs. Post,
p < 0.05
Borghi-Silva et al.,
2015
Brazil
Randomized controlled
trial
10 patients with COPD (7♂;
67.0 ± 7.0 years; FEV1 32.0 ±
11.0%pred; FVC 58.0 ±
15.0%pred)
Aerobic training
70% of peak speed in
CPET
12 weeks
3 sessions/week
30 min/session
Mean of RR and its
standard deviation at rest
(ms)
Pre 17.2 ± 7.3 vs. Post 25.4
± 5.5, p < 0.05
ES = 1.27
Mean of RR and its
standard deviation at
constant speed (ms)
Pre 12.7 ± 5.1 vs. Post 18.3
± 4.7, p > 0.05
ES = 1.14
Square root of the mean
squared differences of
successive RRi at rest (ms)
Pre 11.7 ± 6.0 vs. Post 22.9
± 0.2, p < 0.05
ES = 2.64
Square root of the mean
squared differences of
successive RRi at constant
speed (ms)
Pre 3.5 ± 1.7 vs. Post 16.9 ±
7.0, p < 0.05
ES = 2.63
Nonlinear indices – SD1 at
rest
Pre 7.1 ± 4.2 vs. Post 19.2 ±
11.8, p < 0.05
ES = 1.37
J. Clin. Med. 2019, 8, 1458 20 of 46
Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Nonlinear indices – SD1 at
constant speed
Pre 3.7 ± 1.7 vs. Post 13.6 ±
8.8, p < 0.05
ES = 1.56
Nonlinear indices – SD2 at
rest
Pre 31.2 ± 6.6 vs. Post 46.1
± 22.0, p < 0.05
ES = 0.92
Nonlinear indices – SD2 at
constant speed
Pre 17.3 ± 5.9 vs. Post 25.4
± 6.5, p < 0.05
ES = 1.30
Low frequency (nu)
Pre 0.6 ± 0.2 vs. Post 0.5 ±
0.2, p > 0.05
ES = −0.60
High frequency (nu)
Pre 0.4 ± 0.2 vs. Post 0.5 ±
0.2, p > 0.05
ES = 0.60
Low frequency/High
frequency ratio
Pre 2.4 ± 2.3 vs. Post 1.8 ±
1.7, p > 0.05
ES = −0.31
Sample entropy
Pre 0.7 ± 0.2 vs. Post 0.9 ±
0.2, p > 0.05
ES = 1.03
Campos et al., 2015
Chile Pre-Post study
39 patients with COPD (36%♂;
67.3 ± 8.5 years; FEV1 59.8 ±
21.0%pred; FVC 78.0 ±
20.3%pred)
Arterial hypertension: n = 31
Dyslipidemia: n = 5
Congestive heart failure: n = 3
Pulmonary
rehabilitation
70%–80% of 6MWT
12 weeks
2 sessions/week
90 min/session
Leite et al., 2015
Brazil
Non-randomized
controlled trial
10 patients with COPD (62.0
(60.3; 69.3) years; FEV1 55.0
(39.0; 70.0)%pred; FVC 78.0
(66.3; 83.5)%pred)
Aerobic training
60%–100% of
VO2peak
12 weeks
3 sessions/week
20–50 min/session
Standard deviation of the
mean of all normal RR
intervals (ms)
Pre 19.8 ± 6.2 vs. Post 24.9
± 8.6, p > 0.05
ES = 0.67
Root mean square of
differences between
adjacent normal RR
intervals in a time interval
(ms)
Pre 14.2 ± 5.7 vs. Post 18.3
± 6.2, p > 0.05
ES = 0.69
Spectral component of low
frequency (ms2)
Pre146.1 ± 118.9 vs. Post
177.7 ± 125.6, p > 0.05
ES = 0.26
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Spectral component of low
frequency (nu)
Pre 67.5 ± 16.0 vs. Post 58.5
± 13.6, p > 0.05
ES = −0.61
Spectral component of high
frequency (ms2)
Pre 62.3 ± 46.8 vs. Post
113.2 ± 62.2, p < 0.05
ES = 0.92
Spectral component of high
frequency (nu)
Pre 32.6 ± 15.9 vs. Post 41.5
± 13.6, p > 0.05
ES = 0.60
Low frequency/High
frequency ratio
Pre 2.9 ± 2.2 vs. Post 1.6 ±
0.8, p > 0.05
ES = −0.78
Mkacher et al., 2015
Tunisia
Randomized controlled
trial
68 patients with COPD
Pulmonary rehabilitation
group: 33 (33♂;
61.2 ± 3.2 years; FEV1 38.6 ±
8.6%pred)
Pulmonary
rehabilitation+balance group:
35 (35♂;
58.3 ± 4.3 years; FEV1 39.4 ±
10.3%pred)
All groups:
Pulmonary
rehabilitation
All groups:
6 months
6 sessions/week (3
times/week, 2
sessions/day)
HR at rest (bpm)
Pulmonary rehabilitation
group: Pre 72.7 ± 8.9 vs.
Post 73.0 ± 4.3, p > 0.05
ES = 0.04
Pulmonary
rehabilitation+balance
group: Pre 75.3 ± 3.9 vs.
Post 73.5 ± 4.5, p > 0.05
ES = −0.43
Spielmanns et al.,
2015
Germany
Randomized controlled
trial
36 patients with COPD
Compressed air group: 17 (64.0
± 8.4 years; FEV1 43.0 ±
12.0%pred)
Arterial hypertension: n = 7
Cardiovascular disease: n = 2
Oxygen group: 19 (65.0 ± 8.7
years; FEV1 44.0 ± 10.0%pred)
Arterial hypertension: n = 8
Cardiovascular disease: n = 4
All groups:
Continuous aerobic
training
70%–85% of WRmax
Interval aerobic
training
110%–125% of
WRmax
All groups:
24 weeks
3 sessions/week
30 min/session
Cardoso et al., 2016
Brazil
Non-randomized
controlled trial
10 patients with COPD (65.2 ±
4.2 years; FEV1 41.8 ±
21.3%pred; FVC 60.7 ±
18.0%pred)
Arterial hypertension: n = 7
Pulmonary
rehabilitation
75% of WRmax
60% of 1RM
12 weeks
3 sessions/week
>30 min/session
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Engel et al., 2016
Australia
Randomized controlled
trial
33 patients with COPD (10♂;
65.5 ± 4.0 years; FEV1 1.6 ± 0.5
L; FVC 2.3 ± 0.7 L)
Pulmonary
rehabilitation
16 weeks
Systolic blood pressure
(mmHg)
Mean Pre/Post difference
Group 1: −3.6, 95%CI
(−13.5; 6.3)
Group 2: −10.6, 95%CI
(−19.6; −1.5)
Group 3: −8.3, 95%CI
(−20.5; 3.8)
Diastolic blood pressure
(mmHg)
Mean Pre/Post difference
Group 1: −3.5, 95%CI
(−12.6; 5.6)
Group 2: −7.7, 95%CI
(−17.1; 1.8)
Group 3: −4.7, 95%CI
(−13.5; 4.2)
Boeselt et al., 2017
Germany
Non-randomized
controlled trial
20 patients with COPD (16♂;
65.9 ± 8.2 years; FEV1 67.9 ±
29.2%pred)
Arterial hypertension: n = 5
Cardiovascular disease: n = 2
Strength training
35%–75% of 1RM
3 months
2 sessions/week
90 min/session
Kanao et al., 2017
Japan Pre-Post study
29 patients with COPD (26♂;
73.2 ± 5 years; FEV1 51.0 ±
121.3%pred)
Arterial hypertension: n = 10
Cardiovascular disease: n = 5
Pulmonary
rehabilitation
60% of WRpeak
12 weeks
2 sessions/week
Pacheco et al., 2017
Spain Observational study
35 patients with COPD
(88.6%♂; 65.1 ± 9.0 years; FEV1
42.2 ± 10.5; FVC 67.8 ±
13.3%pred; DLCO 47.9 ±
21.0%pred
Arterial hypertension: n = 20
Dyslipidemia: n = 6
Congestive heart failure: n = 7
Ischemic cardiomyopathy:
n = 3
Pulmonary
rehabilitation
70% of WRmax
75% of 1RM
12 weeks
3 sessions/week
>30 min/session
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Papp et al., 2017
Sweden
Randomized controlled
trial
17 patients with COPD (7♂;
69.0 (62.0; 72.1) years; FEV1
64.3 ± 15.4%pred)
Aerobic and strength
training
70% of 1RM
Perceived exertion
12–14 in the Borg
12 weeks
2 sessions/week
60–70 min/session
HR at rest (bpm) Mean Pre/Post difference0.6, p = 0.82
Systolic blood pressure at
rest (mmHg)
Mean Pre/Post difference
4.2
Diastolic blood pressure at
rest (mmHg)
Mean Pre/Post difference
5.7, p = 0.04
Number of pairs of adjacent
NN intervals differing by
more than 50 ms in the 5
min recording divided by
the total number of all NN
intervals (%)
Mean Pre/Post difference
0.6, p = 0.56
Square root of the mean of
the sum of the squares of
differences between
adjacent NN intervals
Mean Pre/Post difference
−3.2, p = 0.27
Vasilopoulou et al.,
2017
Greece
Randomized controlled
trial
50 patients with COPD (38♂;
66.7 ± 7.3 years; FEV1 51.8 ±
17.3%pred; FVC 78.4 ±
18.4%pred; DLCO 57.0 ±
20.4%pred)
Cardiovascular disease: n = 15
Pulmonary
rehabilitation
12 months
2 sessions/week
Lan et al., 2018
Taiwan
Pre-Post study
43 patients with COPD (31♂;
69.7 ± 8.8 years; FEV1 49.5 ±
19.9%pred; FVC 76.5 ±
22.3%pred)
Pulmonary
rehabilitation
12 weeks
2 sessions/week
40 min/session
HR at rest Pre vs. Post p > 0.05
Mean blood pressure at rest Pre vs. Post p < 0.05
Oxygen pulse Pre vs. Post p < 0.05
Moezy et al., 2018
Iran
Randomized controlled
trial
14 patients with COPD
(71.4%♂;
64.7 ± 7.5 years; FEV1 60.2 ±
14.0%pred)
Aerobic training
Dyspnoea 3–4 in the
mBorg
12 weeks
3 sessions/week
15–60 min/session
HR at rest (bpm)
Pre 80.4 ± 12.6 vs. Post 77.8
± 11.9, p = 0.968
ES = −0.21
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Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Silva et al., 2018
Brazil
Randomized controlled
trial
48 patients with COPD
Elastic resistances group: 32
(69.4 ± 9.0 years; FEV1 50.7 ±
16.7%pred; FVC 72.5 ±
13.2%pred)
Weight machines group: 16
(64.9 ± 11.2 years; FEV1 45.4 ±
15.2%pred; FVC 66.1 ±
14.0%pred)
All groups:
Strength training
All groups:
12 weeks
3 sessions/week
60 min/session
Total cholesterol (mg/dL)
Elastic resistances group:
Pre 108.4 ± 25.3 vs. Post
104.6 ± 14.3, p > 0.05
ES = −0.18
Weight machines group:
Pre 84.6 ± 27.0 vs. Post 71.1
± 32.0, p > 0.05
ES = −0.46
Cholesterol – HDL (mg/dL)
Elastic resistances group:
Pre 58.4 ± 23.2 vs. Post 63.4
± 17.3, p > 0.05
ES = 0.24
Weight machines group:
Pre 132.3 ± 43.6 vs. Post
150.3 ± 52.3, p > 0.05
ES = 0.37
Cholesterol – Triglycerides
(mg/dL)
Elastic resistances group:
Pre 154.2 ± 62.3 vs. Post
129.7 ± 40.3, p > 0.05
ES = −0.47
Weight machines group:
Pre 104.8 ± 38.4 vs. Post
99.9 ± 32.9, p > 0.05
ES = −0.14
Total cholesterol/HDL ratio
(mg/dL)
Elastic resistances group:
Pre 50.7 ± 39.9 vs. Post 40.9
± 25.8, p > 0.05
ES = −0.29
Weight machines group:
Pre 71.9 ± 31.2 vs. Post 61.3
± 15.4, p > 0.05
ES = −0.43
Charikiopoulou et
al., 2019
Greece
Non-controlled study
32 patients with COPD (25♂;
66.0 ± 6.0 years; FEV1 43.1 ±
15.1%pred; DLCO 38.2 ±
22.8%pred)
Cardiovascular disease: n = 22
Pulmonary
rehabilitation
100% of WRmax
13 weeks
2 sessions/week
≥1 h/session
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Table 2. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Mekki et al., 2019
Tunisia
Randomized controlled
trial
45 patients with COPD
Pulmonary
rehabilitation+NMES group:
25 (25♂;
59.6 ± 4.8 years; FEV1 57.7 ±
14.4%pred; FVC 76.0 ±
13.2%pred)
Pulmonary rehabilitation
group: 20 (20♂;
59.5 ± 3.1 years; FEV1 57.1 ±
10.2%pred; FVC 75.9 ±
7.8%pred)
All groups:
Pulmonary
rehabilitation
60%–70% of HRmax
in the 6MWT
50%–85% of 10RM
All groups:
6 months
3 sessions/week
80 min/session
HR at rest (bpm)
Pulmonary
rehabilitation+NMES
group: Pre 80.0 ± 9.0 vs.
Post 78.0 ± 9.0, p < 0.001
ES = −0.22
Pulmonary rehabilitation
group: Pre 80.0 ± 7.0 vs.
Post 77.0 ± 7.0, p < 0.001
ES = −0.43
Silva et al., 2019
Brazil
Randomized controlled
trial
19 patients with COPD
Elastic resistances group: 9
(65.9 ± 8.9 years; FEV1 45.2 ±
16.2%pred; FVC 64.7 ±
19.0%pred)
Weight machines group: 10
(65.5 ± 9.8 years; FEV1 57.6 ±
16.3%pred; FVC 79.8 ±
11.5%pred)
All groups:
Strength training
All groups:
12 weeks
3 sessions/week
60 min/session
HR (bpm)
Elastic resistances group:
Pre 74.1 ± 8.8 vs. Post 76.8
± 8.9, p > 0.05
ES = 0.30
Weight machines group:
Pre 71.4 ± 6.4 vs. Post 68.9
± 9.9, p > 0.05
ES = −0.30
Systolic blood pressure
(mmHg)
Elastic resistances group:
Pre 120.0 (105.0; 135.0) vs.
Post 120.0 (110.0; 120.0),
p > 0.05
Weight machines group:
Pre 120.0 (117.5; 130.0) vs.
Post 120.0 (110.0; 120.0),
p > 0.05
Diastolic blood pressure
(mmHg)
Elastic resistances group:
Pre 70.0 (70.0; 80.0) vs. Post
70.0 (70.0; 75.0), p > 0.05
Weight machines group:
Pre 80.0 (70.0; 90.0) vs. Post
75.0 (67.5; 80.0), p > 0.05
Data are presented as mean ± standard deviation or median (interquartile range), unless otherwise stated. Legend: 6MWT, 6-min walk test; 12MWT, 12-min walk test; 1RM, one repetition
maximum; 10RM, ten repetition maximum; 15RM, fifteen repetition maximum; 95%CI, 95% confidence interval; %pred, percentage predicted; COPD, chronic obstructive pulmonary
disease; CPET, cardiopulmonary exercise test; DLCO, diffusing capacity for carbon monoxide; ES, effect size; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HDL, high
density lipoprotein; HR, heart rate; HRmax, maximum heart rate; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; LDL, low density lipoprotein; mBorg, modified Borg
scale; NMES, neuromuscular electrical stimulation; VO2max, maximal oxygen uptake; VO2peak, peak oxygen uptake; WR, work rate; WRmax, maximal work rate; WRpeak, peak work rate.
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Table 3. Characteristics of the studies in patients with asthma included in phase 2 (i.e., studies that specified the prevalence of cardiovascular comorbidities in the
baseline characteristics of the population under study and/or reported at least one cardiovascular outcome) (n = 2).
Study and Country Study design Population Intervention Duration andFrequency
Cardiovascular
Outcomes and
Outcome measures
Results on
Cardiovascular
Outcomes
Cochrane et al., 1990
Scotland
Randomized
controlled trial
18 patients with
Asthma (27.0 ± 17.0
years; FEV1 76.0 ±
12.0%pred)
Aerobic and muscle
strength training
75% of HRmax
3 months
3 sessions/week
30 min/session
Oxygen pulse
(mL/beat)
Pre 8.8 ± 2.3 vs. Post
10.8 ± 2.4, p < 0.001
ES = 0.85
Total blood
cholesterol (mmol/L)
Pre 5.4 ± 1.1 vs. Post
5.3 ± 1.1, p > 0.05
ES = −0.09
Cholesterol – HDL
(mmol/L)
Pre 1.7 ± 0.4 vs. Post
1.6 ± 0.3, p > 0.05
ES = −0.28
Cholesterol – LDL
(mmol/L)
Pre 3.2 ± 1.2 vs. Post
2.9 ± 0.9, p > 0.05
ES = −0.28
El-Kader et al., 2016
Saudi Arabia
Randomized
controlled trial
40 patients with
Asthma (23♂; 47.2 ±
6.5 years; FEV1 1.4 ±
0.7 L)
Aerobic training
60%–80% of HRmax
6 months
3 sessions/week
30 min/session
Cholesterol – HDL
(mg/dL)
Pre 34.7 ± 5.6 vs. Post
37.9 ± 4.6, p < 0.05
ES = 0.62
Cholesterol – LDL
(mg/dL)
Pre 133.7 ± 13.2 vs.
Post 120.3 ± 11.5,
p < 0.05
ES = −1.08
Cholesterol –
Triglycerides (mg/dL)
Pre 155.4 ± 12.6 vs.
Post 127.7 ± 11.3,
p < 0.05
ES = −2.31
Data are presented as mean ± standard deviation, unless otherwise stated. Legend: %pred, percentage predicted; ES, effect size; FEV1, forced expiratory volume in 1 s; HDL, high density
lipoprotein; HR, heart rate; HRmax, maximum heart rate; LDL, low density lipoprotein.
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Table 4. Characteristics of the studies in patients with ILD included in phase 2 (i.e., studies that specified the prevalence of cardiovascular comorbidities in the baseline
characteristics of the population under study and/or reported at least one cardiovascular outcome) (n = 8).
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Gaunaurd et al.,
2014
United States of
America
Randomized controlled
trial
11 patients with IPF (71.0 ± 6.0
years; FVC 60.0 ± 11.0%pred;
DLCO 44.0 ± 11.0%pred)
History of heart disease: n = 1
Pulmonary
rehabilitation
70%–80% of HRmax
12 weeks
2 sessions/week
90 min/session
Vainshelboim et al.,
2014
Israel
Randomized controlled
trial
15 patients with IPF (10♂;
68.8 ± 6 years; FEV1 68.5 ±
15.8%pred; FVC 66.1 ±
14.8%pred; DLCO 48.6 ±
17.2%pred)
Arterial hypertension: n = 12
Coronary heart disease: n = 7
Pulmonary hypertension: n = 5
Aerobic and strength
training
50%–70% of WRpeak
70%–90% of average
walking speed in the
6MWT
3–6 in the mBorg
12 weeks
2 sessions/week
60 min/session
HR at rest (bpm)
Mean Pre/Post difference
−2.4 ± 9.1
ES = −0.26
Systolic blood pressure at
rest (mmHg)
Mean Pre/Post difference
−2.9 ± 13.6
ES = −0.21
Diastolic blood pressure at
rest (mmHg)
Mean Pre/Post difference
1.5 ± 7.1 ES = 0.21
Oxygen pulse (ml/beat)
Mean Pre/Post difference
0.9 ± 1.5
ES = 0.62
Marcellis et al., 2015
The Netherlands Pre-Post study
18 patients with Sarcoidosis
(14♂;
50.3 ± 10.4 years; FEV1 93.6 ±
17.0%pred; FVC 102.2 ±
18.1%pred; DLCO 91.2 ±
18.4%pred)
Aerobic and strength
training
40% of 1RM
60% of maximal
walking speed in the
6MWT
50% of WRmax
13 weeks
3 sessions/week
1 h/session
HR at rest (bpm)
Pre 82.7 ± 13.1 vs. Post 77.1
± 12.8, p = 0.11
ES = −0.43
Vainshelboim at al.,
2015
Israel
Randomized controlled
trial
15 patients with IPF (10♂;
68.8 ± 6 years; FVC 66.1 ±
14.8%pred; DLCO 48.6 ±
17.2%pred)
Arterial hypertension: n = 12
Coronary heart disease: n = 7
Pulmonary hypertension: n = 5
Aerobic and strength
training
50%–70% of WRpeak
70%–90% of average
walking speed in the
6MWT
Perceived exertion
3–6 in the mBorg
12 weeks
2 sessions/week
60 min/session
Boström et al., 2016
Sweden
Randomized controlled
trial
18 patients with Systemic
lupus erythematosus (0♂; 52.0
± 10.0 years)
Arterial hypertension: n = 6
Pulmonary
rehabilitation
65%–80% of HRmax
Perceived exertion
13–16 in the Borg
12 weeks
2 sessions/week
60 min/session
HR at rest
Blood pressure at rest
Pre vs. Post, p = 0.04
Pre vs. Post, p > 0.05
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Table 4. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Vainshelboim et al.,
2017
Israel
Randomized controlled
trial
15 patients with IPF (10♂; 68.8
± 6.0 years; FVC 66.1 ±
14.8%pred; DLCO 48.6 ±
17.2%pred)
Arterial hypertension: n = 12
Coronary heart disease: n = 7
Pulmonary hypertension: n = 5
Aerobic and strength
training
50%–70% of WRpeak
70%–90% of average
walking speed in the
6MWT
12 weeks
2 sessions/week
60 min/session
HR (bpm)
Mean Pre/Post difference
−2.4 ± 9.1
ES = −0.26
HR reserve (bpm)
Mean Pre/Post difference
6.7 ± 11.0
ES = 0.61
Systolic blood pressure
(mmHg)
Mean Pre/Post difference
−2.9 ± 13.6
ES = −0.21
Diastolic blood pressure
(mmHg)
Mean Pre/Post difference
1.5 ± 7.1
ES = 0.21
Rate pressure product
(bpm/mmHg)
Mean Pre/Post difference
1685.0 ± 3338.0
ES = 0.50
Left atrium diameter (cm)
Mean Pre/Post difference
0.0 ± 0.5
ES = 0.04
Left atrium area (cm2)
Mean Pre/Post difference
0.2 ± 2.7
ES = 0.07
Left ventricle posterior wall
thickness (cm)
Mean Pre/Post difference
0.0 ± 0.1
ES = 0.30
Intra-ventricular septum
thickness (cm)
Mean Pre/Post difference
0.1 ± 0.1
ES = 0.60
Left ventricle end systolic
diameter index (cm/m2)
Mean Pre/Post difference
−0.1 ± 0.3
ES = −0.40
Left ventricle end diastolic
diameter index (cm/m2)
Mean Pre/Post difference
−0.1 ± 0.3
ES = −0.47
Stroke volume (mL/beat)
Mean Pre/Post difference
−4.5 ± 13.4
ES = −0.34
Cardiac output (L/min)
Mean Pre/Post difference
−0.4 ± 0.8
ES = −0.50
Cardiac index (L/min/m2)
Mean Pre/Post difference
−0.2 ± 0.4
ES = −0.50
J. Clin. Med. 2019, 8, 1458 29 of 46
Table 4. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
1
Ejection fraction (%)
Mean Pre/Post difference
0.8 ± 3.0
ES = 0.27
Fractioning shortening (%)
Mean Pre/Post difference
0.9 ± 6.2
ES = 0.15
Earlier transmitral velocity
(E) (ms)
Mean Pre/Post difference
0.8 ± 16.9
ES = 0.05
Late trasmitral velocity (A)
(ms)
Mean Pre/Post difference
5.1 ± 20.7
ES = 0.25
E/A ratio
Mean Pre/Post difference
0.0 ± 0.4
ES = 0.00
Isovolumic relaxation time
(ms)
Mean Pre/Post difference
9.1 ± 32.1
ES = 0.28
Deceleration time (ms)
Mean Pre/Post difference
11.0 ± 52.7
ES = 0.21
Systolic pulmonary arterial
pressure (mmHg)
Mean Pre/Post difference
−0.5 ± 6.8
ES = −0.07
Peak circulatory power
(mLO2/kg/min/mmHg)
Mean Pre/Post difference
490.0 ± 637.0
ES = 0.77
Peak cardiac power output
(W)
Mean Pre/Post difference
0.3 ± 0.3
ES = 0.94
Peak stroke work
(mLO2/beat/mmHg)
Mean Pre/Post difference
221.0 ± 343.0
ES = 0.64
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Table 4. Cont.
Study and Country Study Design Population Intervention Duration andFrequency
Cardiovascular Outcomes
and Outcome Measures
Results on Cardiovascular
Outcomes
Naz et al., 2018a
Turkey Pre-Post study
14 patients with ILD (5♂; 63.0
(53.0; 70.0) years; FEV1 78.0
(69.0; 83.0)%pred; FVC 74.0
(67.0; 78.0)%pred; DLCO 40.0
(19.0; 45.0)%pred)
Arterial hypertension: n = 7
Congestive heart failure: n = 2
Aerobic and strength
training
80% of peak walking
speed in the 6MWT
70% of WRmax
Dyspnoea and
perceived exertion
4–6 in the mBorg
12 weeks
2 sessions/week
60–90 min/session
Naz et al., 2018b
Turkey
Randomized controlled
trial
9 patients with Sarcoidosis
(33.3%♂;
59.0 (52.0; 64.0) years; FEV1
73.0 (65.0; 85.0)%pred; FVC
76.0 (66.0; 90.0)%pred; DLCO
45.0 (36.0; 54.0)%pred)
Aerobic and strength
training
80% of the peak speed
in the 6MWT
Fatigue 4–6 in the
mBorg
12 weeks
2 sessions/week HR (bpm)
Median Pre/Post difference
0.0 [−6.0; 5.0], p > 0.05
Data are presented as mean ± standard deviation or median (interquartile range), unless otherwise stated. Legend: 6MWT, 6-min walk test; 1RM, one repetition maximum; %pred,
percentage predicted; DLCO, diffusing capacity for carbon monoxide; ES, effect size; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HR, heart rate; HRmax, maximum
heart rate; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; mBorg, modified Borg scale; WR, work rate; WRmax, maximal work rate; WRpeak, peak work rate.
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Most studies (n = 20; 71.4%) presented only small to moderate effects in the cardiovascular
outcome measures reported. Standard deviation of RR intervals [49,108] (n = 2; ES = [0.67; 2.64]) and
root mean square of successive RR interval differences [49,57,108] (n = 3; ES = [0.69; 2.64]) were the
outcome measures presenting the larger effects. In patients with COPD, the effects of exercise training
programmes on resting heart rate resulted in an overall pooled ES of −0.23 (95% confidence interval
−0.33 to −0.13) (Figure 5).
Figure 5. Forest plot of comparison control versus intervention in patients with COPD; outcome: resting
heart rate. ES, effect size; NMES, neuromuscular electrical stimulation; PR, pulmonary rehabilitation.
Regarding the exercise programmes, most studies conducted in patients with COPD performed a
pulmonary rehabilitation programme [33,54,55,57,59,68,80,90,101,104,106,107,121,123,136,167] (n = 16)
or an exercise programme combining aerobic and strength training [38,43–45,54,86,129,130] (n = 8).
Sessions were conducted 2–6 times per week and each session lasted from 15 min to 2 h. Programme
duration varied between 12 weeks and 18 months. A wide range of intensities was used to prescribe
the exercise: 60%–80% of the maximum heart rate, 50%–100% of the peak or maximum oxygen uptake,
50%–125% of the peak or maximum workload, 35%–75% of one-repetition maximum, dyspnoea and
perceived exertion levels between 3–6 on the modified Borg scale and 12–16 on the Borg scale. None of
the studies specified any adjustments to tailor the exercise programmes to patients’ cardiovascular
comorbidities. Only one study [108] described adjusting the training programme in different mesocycles
in order to improve specific cardiovascular outcomes.
Studies conducted in patients with asthma performed either an exercise programme combining
aerobic and strength training for 3 months [189] or aerobic training for 6 months [186]. Sessions
occurred 3 times/week, for 30 min each, at an intensity of 60%–80% of the maximum heart rate. No
specific adjustments to improve specific cardiovascular outcomes were reported.
In patients with ILD, most studies conducted exercise programmes combining aerobic and
strength training [201–203,207–209] (n = 6). The majority of programmes lasted for 12 weeks with 2
sessions/week [196,198,202,203,207–209] (n = 7). Sessions had a duration of 60–90 min and exercise was
prescribed at an intensity of 65%–85% of maximum heart rate, 50%–90% of peak workload, dyspnoea
and perceived exertion levels between 3 and 6 on the modified Borg scale. None of the studies specified
any adjustments to tailor the exercise programmes to patients’ cardiovascular comorbidities.
4. Discussion
To the best of the authors’ knowledge, this is the first comprehensive overview of the scientific
literature summarizing (i) the eligibility criteria in terms of cardiovascular disease used to select
patients with chronic respiratory disease to exercise training studies, (ii) the impact of at least 3 months
of exercise training on cardiovascular outcomes, and (iii) adjustments made to tailor exercise training
prescription to patients with cardiovascular comorbidities. It was found that (i) in the majority of the
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studies (58.9%) patients with cardiovascular comorbidities were excluded a priori, (ii) there is limited
evidence about the impact of exercise training on cardiovascular outcomes in patients with chronic
respiratory diseases, and (iii) none of the studies explicitly mentioned how to tailor exercise training
modalities in light of cardiovascular comorbidities.
A large diversity was found regarding the cardiovascular conditions that are used as exclusion
criteria in exercise-related research. Interestingly, the majority of the exclusion criteria reported
(34/45) are not considered contraindications to exercise training. Indeed, just a minority of the
studies (18.3%) excluded only patients with acute/unstable cardiovascular disease that contraindicated
participation in exercise training. Most studies excluded patients with both stable and unstable
cardiovascular comorbidities, although at least 20%–50% of the patients with COPD, asthma or
ILD present cardiovascular comorbidities [5,7,18,20,210,211]. Thus, by excluding patients with
cardiovascular comorbidities or any other comorbidity that does not present any contraindication to
perform exercise training, translation of knowledge to clinical practice can only be done for a subset, or
sometimes even a minority, of patients. This finding might have a far-reaching consequence, namely
that current knowledge (including clinical guidelines) is disease-centred and, thus, inadequate to
sufficiently support/guide clinicians on how to prescribe exercise for patients with chronic respiratory
diseases and multiple chronic conditions [13,212]. Furthermore, some of the criteria reported (e.g.,
cardiovascular disease) were too vague to allow understanding of which conditions were really
excluded and over 20% of the included studies did not report any information concerning to eligibility
criteria, even though this is key information to ensure clarity and transparency of the research [213].
Exercise training programmes in patients with cardiovascular comorbidities resulted in significant
improvements in general reported outcomes, namely symptoms, functionality, exercise capacity,
muscle strength and health-related quality of life, comparable to the ones usually found in respiratory
patients [22]. However, regarding cardiovascular outcomes, in the majority of the studies (71.4%) only
small to moderate effects were found, with the larger effects being reported for heart rate variability
measurements (ES = [−0.78; 2.64]) and blood lipid profile (ES = [−2.31; 0.62]). Additionally, a small
but significant overall effect of exercise training programmes on resting heart rate of patients with
COPD was found. These results are yet not inferior to the ones previously reported for patients
with cardiovascular diseases, in whom beneficial effects of exercise training have been found for
heart rate variability and heart rate recovery [214], and inconsistent but significant and modest effects
have been reported for arterial blood pressure and blood lipid profile [214–217]. We hypothesized
that several reasons might be contributing to the limited effects found. First, most studies have not
reported any specific adjustments in the exercise prescription to tailor the programme to patients’
cardiovascular comorbidities, although it is plausible that they have made some adjustments without
specific reporting in the published paper. It is known that cardiovascular conditions require specific
considerations when formulating the exercise plan [22], and different recommendations exist based on
the prevalent cardiovascular disease (e.g., coronary artery disease, congestive heart failure, peripheral
arterial disease, pulmonary arterial hypertension) and its severity [218]. Indeed, it is mandatory to
tailor exercise duration, frequency, mode, intensity and monitoring to patients’ specificities and needs,
clinical conditions, cardiovascular phenotype (risk factors and diseases), fitness level, medication
intake (beta blockers, statins, glinides, sulfonylurea), abnormal responses to exercise (myocardial
ischemia, atrial fibrillation, ventricular tachycardia) and rehabilitation goals [1,218–221]. Moreover, the
impact of exercise training relies on this proper tailoring of the exercise programme, since it has been
shown that different exercise prescriptions result in significant differences in clinical outcomes [221].
Future studies should therefore assess the impact of exercise programmes specifically tailored to
patients with co-occurring respiratory disease and cardiovascular comorbidities [7] and report the
intervention in detail. Second, guidelines for cardiac rehabilitation from the leading scientific societies
recommend that exercise should progress from moderate to vigorous intensity, three times per week [21].
Nevertheless, in some of the included studies, patients exercised at lower intensities and/or fewer
times per week, which might have also contributed to the relative lack of effects since the minimum
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dose of exercise for cardiovascular benefits (>150 min/week of endurance training, energy expenditure
1000–2000 kcal/week) might have not been reached [218,222]. Third, some of the included studies only
used strength training in their exercise programmes. Indeed, strength training has been recommended
in patients with cardiovascular diseases, but as an adjunct to aerobic training, the last being a core
component in these patients’ rehabilitation [21]. From these observations, it became clear that current
exercise prescription to patients with COPD, asthma or ILD with cardiovascular comorbidities is
far from optimal and deserves significant reconsideration. Nonetheless, digital support on how to
prescribe exercise in these patients in accordance to all the different clinical guidelines for different
cardiovascular diseases is available, and thus could be used to support health professionals [218]. Lastly,
most studies including patients with cardiovascular comorbidities only focused on the assessment
of resting heart rate. Although this is a relevant outcome measure and results from meta-analysis in
patients with COPD favour intervention, recommendations for patients with cardiovascular diseases
advocate a more comprehensive assessment, including outcomes such as arterial blood pressure,
blood lipid profile or echocardiography, that are also more in line with the aims of rehabilitation in
these patients [223,224]. Therefore, outcomes should be better targeted to patients’ cardiovascular
comorbidities [19].
Besides the known prevalence and increased risk of morbidity and mortality that
cardiovascular comorbidities impose on patients with chronic respiratory diseases [7,211], only
three studies [196,207,209] (all conducted in the last 5 years) included patients with cardiovascular
comorbidities and assessed cardiovascular outcome measures. This denotes the current gap in the
literature regarding exercise programmes and emphasises the need for specific studies focusing on
cardiovascular outcomes in these patients.
This systematic review has a number of limitations that need to be acknowledged. First, as it was
anticipated that a large number of studies would be found, only exercise programmes lasting at least
12 weeks were included, which might have led to the loss of other relevant studies. Nevertheless, 12
weeks has been recommended as the minimum exercise duration required to reach benefits in patients
with cardiovascular disease [25]. Second, as only few studies including patients with ILD were found,
all types of ILD were grouped, although different types of ILD present different characteristics and
possibly different cardiovascular comorbidities and responses to exercise training programmes. Third,
most of the included studies were of weak quality. Nonetheless, since in exercise interventions blinding
of participants is impossible and patients are usually referred by physicians to ensure their safety, it
was virtually impossible to ensure strong quality in the quality assessment tool used.
5. Conclusions
Although a large number of studies explored the effects of at least 3 months of exercise training in
patients with chronic respiratory diseases, only few included patients with cardiovascular comorbidities.
Limited effects of the exercise programmes were found on cardiovascular outcome measures, possibly
due to the lack of tailoring of the exercise training prescription and comprehensiveness of the
cardiovascular outcome measures. Future studies focusing on patients with combined respiratory and
cardiovascular diseases and exploring the effects of exercise programmes specifically tailored to these
patients are needed to bridge the gap in the literature.
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Appendix A Search Strategy
A1. PubMed
#1 Search (“chronic obstructive pulmonary disease” OR “copd” OR “asthma” OR “interstitial lung
diseas*” OR “ILD" OR "parenchymal lung disease" OR "parenchymal lung disorder" OR "pulmonary
fibrosis" OR “sarcoidosis” OR "interstitial pneumonia" OR "connective tissue disease" OR "collagen
vascular disease" OR "occupational lung disease" OR "hypersensitivity pneumonitis" OR “asbestosis”
OR “silicosis” OR “beryliosis” OR "respiratory bronchiolitis" OR "desquamative interstitial pneumonia"
OR "cryptogenic organising pneumonia" OR "lymphoid interstitial pneumonia" OR "pleuroparenchymal
fibroelastosis" OR “pneumoconiosis” OR "extrinsic allergic alveolitis" OR "Iatrogenic interstitial lung
disease" OR "post-infectious interstitial lung disease" OR “granulomatose” OR "systemic sclerosis"
OR “polymyositis” OR “dermatomyositis” OR "systemic lupus erythematosus" OR "Hamman-Rich
syndrome" OR “bagassosis” OR “histiocytosis” OR "fibrotic interstitial lung disease" OR "fibrotic lung
disease")
#2 Search (“exercise” OR “walking” OR “aerobic training” OR “endurance training” OR “interval
training” OR “high-intensity training” OR “resistance training” OR “strength training”)
#3 Search ("Pulmonary Disease, Chronic Obstructive” OR “Asthma” OR “Lung Diseases,
Interstitial” OR “Pulmonary Fibrosis” OR “Sarcoidosis” OR “Connective Tissue Diseases” OR
“Alveolitis, Extrinsic Allergic” OR “Asbestosis” OR “Silicosis” OR “Pneumoconiosis” OR “Scleroderma,
Systemic” OR “Polymyositis” OR “Dermatomyositis” OR “Lupus Erythematosus, Systemic” OR
“Histiocytosis”))
#4 Search (“Exercise” OR “Walking” OR “Endurance Training” OR “Resistance Training”)
#5 Search (#1 AND #2 [Title/Abstract]) OR (#3 AND #4 [MeSH Terms])
A2. Cochrane, Scopus and Web of Science
#1 Search (“chronic obstructive pulmonary disease” OR copd OR asthma OR “interstitial lung
diseas*” OR ILD OR "parenchymal lung disease" OR "parenchymal lung disorder" OR "pulmonary
fibrosis" OR sarcoidosis OR "interstitial pneumonia" OR "connective tissue disease" OR "collagen
vascular disease" OR "occupational lung disease" OR "hypersensitivity pneumonitis" OR asbestosis OR
silicosis OR beryliosis OR "respiratory bronchiolitis" OR "desquamative interstitial pneumonia" OR
"cryptogenic organising pneumonia" OR "lymphoid interstitial pneumonia" OR "pleuroparenchymal
fibroelastosis" OR pneumoconiosis OR "extrinsic allergic alveolitis" OR "Iatrogenic interstitial lung
disease" OR "post-infectious interstitial lung disease" OR granulomatose OR "systemic sclerosis" OR
polymyositis OR dermatomyositis OR "systemic lupus erythematosus" OR "Hamman-Rich syndrome"
OR bagassosis OR histiocytosis OR "fibrotic interstitial lung disease" OR "fibrotic lung disease")
#2 Search (“exercise” OR “walking” OR “aerobic training” OR “endurance training” OR “interval
training” OR “high-intensity training” OR “resistance training” OR “strength training”)
#3 Search (#1 AND #2)
References
1. Armstrong, M.; Vogiatzis, I. Personalized exercise training in chronic lung diseases. Respirology 2019, 24,
854–862. [CrossRef] [PubMed]
2. Bousquet, J.; Kiley, J.; Bateman, E.; Viegi, G.; Cruz, A.; Khaltaev, N.; Khaled, N.A.; Baena-Cagnani, C.;
Barreto, M.; Billo, N. Prioritised research agenda for prevention and control of chronic respiratory diseases.
Eur. Respir. J. 2010, 36, 995–1001. [CrossRef] [PubMed]
3. Prince, M.J.; Wu, F.; Guo, Y.; Robledo, L.M.G.; O’Donnell, M.; Sullivan, R.; Yusuf, S. The burden of disease in
older people and implications for health policy and practice. Lancet 2015, 385, 549–562. [CrossRef]
4. World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region,
2000–2016; WHO: Geneva, Switzerland, 2018.
J. Clin. Med. 2019, 8, 1458 35 of 46
5. Mannino, D.M.; Thorn, D.; Swensen, A.; Holguin, F. Prevalence and outcomes of diabetes, hypertension and
cardiovascular disease in COPD. Eur. Respir. J. 2008, 32, 962–969. [CrossRef] [PubMed]
6. Boulet, L.-P.; Boulay, M.-È. Asthma-related comorbidities. Expert Rev. Respir. Med. 2011, 5, 377–393.
[CrossRef] [PubMed]
7. Franssen, F.M.; Rochester, C.L. Comorbidities in patients with COPD and pulmonary rehabilitation: Do they
matter? Eur Respir. Soc 2014, 23, 131–141. [CrossRef] [PubMed]
8. Houben-Wilke, S.; Spruit, M.A.; Uszko-Lencer, N.H.; Otkinska, G.; Vanfleteren, L.E.; Jones, P.W.; Wouters, E.F.;
Franssen, F.M. Echocardiographic abnormalities and their impact on health status in patients with COPD
referred for pulmonary rehabilitation. Respirology 2017, 22, 928–934. [CrossRef]
9. Hyldgaard, C.; Hilberg, O.; Bendstrup, E. How does comorbidity influence survival in idiopathic pulmonary
fibrosis? Respir. Med. 2014, 108, 647–653. [CrossRef]
10. King, C.; Nathan, S.D. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and
other fibrotic lung diseases. Curr. Opin. Pulm. Med. 2013, 19, 466–473. [CrossRef]
11. Soriano, J.B.; Visick, G.T.; Muellerova, H.; Payvandi, N.; Hansell, A.L. Patterns of comorbidities in newly
diagnosed COPD and asthma in primary care. Chest 2005, 128, 2099–2107. [CrossRef]
12. Triest, F.J.; Singh, S.J.; Vanfleteren, L.E. Cardiovascular risk, chronic obstructive pulmonary disease and
pulmonary rehabilitation: Can we learn from cardiac rehabilitation? Chronic Respir. Dis. 2016, 13, 286–294.
[CrossRef] [PubMed]
13. Houben-Wilke, S.; Triest, F.J.; Franssen, F.M.; Janssen, D.J.; Wouters, E.F.; Vanfleteren, L.E. Revealing
methodological challenges in chronic obstructive pulmonary disease studies assessing comorbidities: A
narrative review. Chronic Obstr. Pulm. Dis. J. Copd. Found. 2019, 6, 166. [CrossRef] [PubMed]
14. Divo, M.; Cote, C.; de Torres, J.P.; Casanova, C.; Marin, J.M.; Pinto-Plata, V.; Zulueta, J.; Cabrera, C.;
Zagaceta, J.; Hunninghake, G. Comorbidities and risk of mortality in patients with chronic obstructive
pulmonary disease. Am. J. Respir. Crit. Care Med. 2012, 186, 155–161. [CrossRef] [PubMed]
15. Kreuter, M.; Ehlers-Tenenbaum, S.; Palmowski, K.; Bruhwyler, J.; Oltmanns, U.; Muley, T.; Heussel, C.P.;
Warth, A.; Kolb, M.; Herth, F.J. Impact of comorbidities on mortality in patients with idiopathic pulmonary
fibrosis. PLoS ONE 2016, 11, e0151425. [CrossRef] [PubMed]
16. Miller, J.; Edwards, L.D.; Agustí, A.; Bakke, P.; Calverley, P.M.; Celli, B.; Coxson, H.O.; Crim, C.; Lomas, D.A.;
Miller, B.E. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 2013,
107, 1376–1384. [CrossRef] [PubMed]
17. Terzano, C.; Conti, V.; Di Stefano, F.; Petroianni, A.; Ceccarelli, D.; Graziani, E.; Mariotta, S.; Ricci, A.;
Vitarelli, A.; Puglisi, G. Comorbidity, hospitalization, and mortality in COPD: Results from a longitudinal
study. Lung 2010, 188, 321–329. [CrossRef] [PubMed]
18. Cazzola, M.; Calzetta, L.; Bettoncelli, G.; Cricelli, C.; Romeo, F.; Matera, M.G.; Rogliani, P. Cardiovascular
disease in asthma and COPD: A population-based retrospective cross-sectional study. Respir. Med. 2012, 106,
249–256. [CrossRef]
19. Crisafulli, E.; Costi, S.; Luppi, F.; Cirelli, G.; Cilione, C.; Coletti, O.; Fabbri, L.M.; Clini, E.M. Role of
comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008, 63,
487–492. [CrossRef]
20. Margaritopoulos, G.A.; Antoniou, K.M.; Wells, A.U. Comorbidities in interstitial lung diseases. Eur. Respir.
Rev. 2017, 26, 160027. [CrossRef]
21. Price, K.J.; Gordon, B.A.; Bird, S.R.; Benson, A.C. A review of guidelines for cardiac rehabilitation exercise
programmes: Is there an international consensus? Eur. J. Prev. Cardiol. 2016, 23, 1715–1733. [CrossRef]
22. Spruit, M.A.; Singh, S.J.; Garvey, C.; ZuWallack, R.; Nici, L.; Rochester, C.; Hill, K.; Holland, A.E.; Lareau, S.C.;
Man, W.D.-C. An official American Thoracic Society/European Respiratory Society statement: Key concepts
and advances in pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 2013, 188, e13–e64. [CrossRef]
[PubMed]
23. Hornikx, M.; Van Remoortel, H.; Lehouck, A.; Mathieu, C.; Maes, K.; Gayan-Ramirez, G.; Decramer, M.;
Troosters, T.; Janssens, W. Vitamin D supplementation during rehabilitation in COPD: A secondary analysis
of a randomized trial. Respir. Res. 2012, 13, 84. [CrossRef] [PubMed]
24. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 1458 36 of 46
25. Man, W.D.; Chowdhury, F.; Taylor, R.S.; Evans, R.A.; Doherty, P.; Singh, S.J.; Booth, S.; Thomason, D.;
Andrews, D.; Lee, C. Building consensus for provision of breathlessness rehabilitation for patients with
chronic obstructive pulmonary disease and chronic heart failure. Chronic Respir. Dis. 2016, 13, 229–239.
[CrossRef] [PubMed]
26. Rochester, C.L.; Vogiatzis, I.; Holland, A.E.; Lareau, S.C.; Marciniuk, D.D.; Puhan, M.A.; Spruit, M.A.;
Masefield, S.; Casaburi, R.; Clini, E.M. An official American Thoracic Society/European Respiratory Society
policy statement: Enhancing implementation, use, and delivery of pulmonary rehabilitation. Am. J. Respir.
Crit. Care Med. 2015, 192, 1373–1386. [CrossRef]
27. Thomas, B.; Ciliska, D.; Dobbins, M.; Micucci, S. A process for systematically reviewing the literature:
Providing the research evidence for public health nursing interventions. World Views Evid. Based Nurs. 2004,
1, 176–184. [CrossRef]
28. Landis, J.R.; Koch, G.G. The measurement of observer agreement for categorical data. Biometrics 1977, 33,
159–174. [CrossRef]
29. Morris, S.B.; DeShon, R.P. Combining effect size estimates in meta-analysis with repeated measures and
independent-groups designs. Psychol. Methods 2002, 7, 105. [CrossRef]
30. Cohen, J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed.; Erlbaum Associates: Hillsdale, MI, USA,
1988.
31. Abd El-Kader, S.M.; Al-Jiffri, O.H. Exercise alleviates depression related systemic inflammation in chronic
obstructive pulmonary disease patients. Afr. Health Sci. 2016, 16, 1078–1088. [CrossRef]
32. Abd El-Kader, S.M.; Al-Jiffri, O.H.; Al-Jiffri, H.O. Aerobic exercise training modulates bone mineral status in
patients with chronic obstructive pulmonary disease. Eur. J. Gen. Med. 2016, 13, 51–54. [CrossRef]
33. Almadana Pacheco, V.; Pavon Masa, M.; Gomez-Bastero Fernandez, A.P.; Muniz Rodriguez, A.M.; Tallon
Moreno, R.; Montemayor Rubio, T. Patient Profile of Drop-Outs From a Pulmonary Rehabilitation Program.
Arch. De Bronconeumol. 2017, 53, 257–262. [CrossRef] [PubMed]
34. Altenburg, W.A.; Duiverman, M.L.; Ten Hacken, N.H.; Kerstjens, H.A.; de Greef, M.H.; Wijkstra, P.J.;
Wempe, J.B. Changes in the endurance shuttle walk test in COPD patients with chronic respiratory failure after
pulmonary rehabilitation: The minimal important difference obtained with anchor- and distribution-based
method. Respir. Res. 2015, 16, 27. [CrossRef] [PubMed]
35. Amin, S.; Abrazado, M.; Quinn, M.; Storer, T.W.; Tseng, C.H.; Cooper, C.B. A controlled study of
community-based exercise training in patients with moderate COPD. BMC Pulm. Med. 2014, 14, 125.
[CrossRef] [PubMed]
36. Arnardóttir, R.H.; Boman, G.; Larsson, K.; Hedenström, H.; Emtner, M. Interval training compared with
continuous training in patients with COPD. Respir. Med. 2007, 101, 1196–1204. [CrossRef] [PubMed]
37. Averna, T.; Brunelli, S.; Delussu, A.S.; Porcacchia, P.; Lucarelli, E.; Polidori, L.; Traballesi, M. Effects of a
moderately intensive, 12-week training program on participants over 60 years of age with chronic obstructive
pulmonary disease. Med. Dello Sport 2009, 62, 299–313.
38. Barakat, S.; Michele, G.; George, P.; Nicole, V.; Guy, A. Outpatient pulmonary rehabilitation in patients with
chronic obstructive pulmonary disease. Int. J. Chronic Obstr. Pulm. Dis. 2008, 3, 155–162.
39. Bendstrup, K.E.; Jensen, J.I.; Holm, S.; Bengtsson, B. Out-patient rehabilitation improves activities of daily
living, quality of life and exercise tolerance in chronic obstructive pulmonary disease. Eur. Respir. J. 1997, 10,
2801–2806. [CrossRef] [PubMed]
40. Bernard, S.; Whittom, F.; Leblanc, P.; Jobin, J.; Belleau, R.; Berube, C.; Carrier, G.; Maltais, F. Aerobic and
strength training in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999,
159, 896–901. [CrossRef]
41. Berry, M.J.; Adair, N.E.; Sevensky, K.S.; Quinby, A.; Lever, H.M. Inspiratory muscle training and whole-body
reconditioning in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996, 153, 1812–1816.
[CrossRef]
42. Berry, M.J.; Jack Rejeski, W.; Adair, N.E.; Zaccaro, D. Exercise rehabilitation and chronic obstructive pulmonary
disease stage. Am. J. Respir. Crit. Care Med. 1999, 160, 1248–1253. [CrossRef]
43. Berry, M.J.; Rejeski, W.J.; Adair, N.E.; Ettinger Jr, W.H.; Zaccaro, D.J.; Sevick, M.A. A randomized, controlled
trial comparing long-term and short-term exercise in patients with chronic obstructive pulmonary disease. J.
Cardiopulm. Rehabil. 2003, 23, 60–68. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 1458 37 of 46
44. Berry, M.J.; Rejeski, W.J.; Miller, M.E.; Adair, N.E.; Lang, W.; Foy, C.G.; Katula, J.A. A lifestyle activity
intervention in patients with chronic obstructive pulmonary disease. Respir. Med. 2010, 104, 829–839.
[CrossRef] [PubMed]
45. Berry, M.J.; Sheilds, K.L.; Adair, N.E. Comparison of Effects of Endurance and Strength Training Programs in
Patients with COPD. COPD 2018, 15, 192–199. [CrossRef] [PubMed]
46. Bingisser, R.M.; Joos, L.; Frühauf, B.; Caravatti, M.; Knoblauch, A.; Villiger, P.M. Pulmonary rehabilitation in
outpatients with asthma or chronic obstructive lung disease. Swiss Med Wkly. 2001, 131, 407–411. [PubMed]
47. Bisca, G.W.; Proenca, M.; Salomao, A.; Hernandes, N.A.; Pitta, F. Minimal detectable change of the London
chest activity of daily living scale in patients with COPD. J. Cardiopulm. Rehabil. Prev. 2014, 34, 213–216.
[CrossRef]
48. Boeselt, T.; Nell, C.; Lutteken, L.; Kehr, K.; Koepke, J.; Apelt, S.; Veith, M.; Beutel, B.; Spielmanns, M.;
Greulich, T.; et al. Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary
Disease: A Controlled Study. Respir. Int. Rev. Thorac. Dis. 2017, 93, 301–310. [CrossRef] [PubMed]
49. Borghi-Silva, A.; Mendes, R.G.; Trimer, R.; Oliveira, C.R.; Fregonezi, G.A.; Resqueti, V.R.; Arena, R.;
Sampaio-Jorge, L.M.; Costa, D. Potential effect of 6 versus 12-weeks of physical training on cardiac autonomic
function and exercise capacity in chronic obstructive pulmonary disease. Eur. J. Phys. Rehabil. Med. 2015, 51,
211–221.
50. Burtin, C.; Langer, D.; van Remoortel, H.; Demeyer, H.; Gosselink, R.; Decramer, M.; Dobbels, F.; Janssens, W.;
Troosters, T. Physical Activity Counselling during Pulmonary Rehabilitation in Patients with COPD: A
Randomised Controlled Trial. PLoS ONE 2015, 10, e0144989. [CrossRef]
51. Burtin, C.; Saey, D.; Saglam, M.; Langer, D.; Gosselink, R.; Janssens, W.; Decramer, M.; Maltais, F.; Troosters, T.
Effectiveness of exercise training in patients with COPD: The role of muscle fatigue. Eur. Respir. J. 2012, 40,
338–344. [CrossRef]
52. Cambach, W.; Chadwick-Straver, R.V.; Wagenaar, R.C.; van Keimpema, A.R.; Kemper, H.C. The effects
of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: A
randomized controlled trial. Eur. Respir. J. 1997, 10, 104–113. [CrossRef]
53. Camillo, C.A.; Laburu, V.D.M.; Gonalves, N.S.; Cavalheri, V.; Tomasi, F.P.; Hernandes, N.A.; Ramos, D.;
Marquez Vanderlei, L.C.; Cipulo Ramos, E.M.; Probst, V.S.; et al. Improvement of heart rate variability after
exercise training and its predictors in COPD. Respir. Med. 2011, 105, 1054–1062. [CrossRef] [PubMed]
54. Campos, A.A.; Cabrera, R.O.; Arancibia, H.F. Respiratory rehabilitation in COPD patients: Experience in a
rural primary health care center. Rev. Chil. De Enferm. Respir. 2015, 31, 77–85.
55. Charikiopoulou, M.; Nikolaidis, P.T.; Knechtle, B.; Rosemann, T.; Rapti, A.; Trakada, G. Subjective and
Objective Outcomes in Patients With COPD After Pulmonary Rehabilitation—The Impact of Comorbidities.
Front. Physiol. 2019, 10, 286. [CrossRef] [PubMed]
56. Chen, R.; Chen, R.; Chen, X.; Chen, L. Effect of endurance training on expiratory flow limitation and dynamic
hyperinflation in patients with stable chronic obstructive pulmonary disease. Intern. Med. J. 2014, 44, 791–800.
[CrossRef] [PubMed]
57. Cheng, S.T.; Wu, Y.K.; Yang, M.C.; Huang, C.Y.; Huang, H.C.; Chu, W.H.; Lan, C.C. Pulmonary rehabilitation
improves heart rate variability at peak exercise, exercise capacity and health-related quality of life in chronic
obstructive pulmonary disease. Heart Lung J. Crit. Care 2014, 43, 249–255. [CrossRef] [PubMed]
58. Clark, C.J.; Cochrane, L.M.; Mackay, E.; Paton, B. Skeletal muscle strength and endurance in patients with
mild COPD and the effects of weight training. Eur. Respir. J. 2000, 15, 92–97. [CrossRef] [PubMed]
59. Corhay, J.L.; Nguyen, D.; Duysinx, B.; Graas, C.; Pirnay, F.; Bury, T.; Louis, R. Should we exclude elderly
patients with chronic obstructive pulmonary disease from a long-time ambulatory pulmonary rehabilitation
programme? J. Rehabil. Med. 2012, 44, 466–472. [CrossRef] [PubMed]
60. Cortopassi, F.; Castro, A.A.; Porto, E.F.; Colucci, M.; Fonseca, G.; Torre-Bouscoulet, L.; Iamonti, V.; Jardim, J.R.
Comprehensive exercise training improves ventilatory muscle function and reduces dyspnea perception
in patients with COPD. Monaldi Arch. Chest Dis. Arch. Monaldi Per Le Mal. Del Torace 2009, 71, 106–112.
[CrossRef]
61. Covey, M.K.; Collins, E.G.; Reynertson, S.I.; Dilling, D.F. Resistance training as a preconditioning strategy for
enhancing aerobic exercise training outcomes in COPD. Respir. Med. 2014, 108, 1141–1152. [CrossRef]
J. Clin. Med. 2019, 8, 1458 38 of 46
62. Covey, M.K.; McAuley, E.; Kapella, M.C.; Collins, E.G.; Alex, C.G.; Berbaum, M.L.; Larson, J.L. Upper-Body
Resistance Training and Self-Efficacy Enhancement in COPD. J. Pulm. Respir. Med. 2012, 1 (Suppl. 9.).
[CrossRef]
63. Cox, N.J.M.; Hendricks, J.C.; Binkhorst, R.A.; van Herwaarden, C.L.A. A pulmonary rehabilitation program
for patients with asthma and mild chronic obstructive pulmonary diseases (COPD). Lung Int. J. Lungs Airw.
Breath 1993, 171, 235–244. [CrossRef]
64. Crimi, C.; Heﬄer, E.; Augelletti, T.; Campisi, R.; Noto, A.; Vancheri, C.; Crimi, N. Utility of ultrasound
assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients. Int. J.
Chronic Obstr. Pulm. Dis. 2018, 13, 3131–3139. [CrossRef] [PubMed]
65. Cruz, J.; Brooks, D.; Marques, A. Impact of feedback on physical activity levels of individuals with chronic
obstructive pulmonary disease during pulmonary rehabilitation: A feasibility study. Chron. Respir. Dis. 2014,
11, 191–198. [CrossRef] [PubMed]
66. Cruz, J.; Brooks, D.; Marques, A. Walk2Bactive: A randomised controlled trial of a physical activity-focused
behavioural intervention beyond pulmonary rehabilitation in chronic obstructive pulmonary disease. Chron.
Respir. Dis. 2016, 13, 57–66. [CrossRef] [PubMed]
67. Da Costa, C.C.; de Azeredo Lermen, C.; Colombo, C.; Canterle, D.B.; Machado, M.L.L.; Kessler, A.;
Teixeira, P.J.Z. Effect of a Pulmonary Rehabilitation Program on the levels of anxiety and depression and
on the quality of life of patients with chronic obstructive pulmonary disease. Rev. Port. Pneumol. 2014, 20,
299–304. [CrossRef] [PubMed]
68. Da Silva Cardoso, M.C.; Sayão, L.B.; Souza, R.M.P.; De Melo Marinho, P.E. Pulmonary rehabilitation and
whole-body vibration in chronic obstructive pulmonary disease. Mot. Rev. De Educ. Fis. 2016, 22, 44–50.
[CrossRef]
69. da Silva, G.P.; Nascimento, F.A.; Macedo, T.P.; Morano, M.T.; Mesquita, R.; Pereira, E.D. Religious coping and
religiosity in patients with COPD following pulmonary rehabilitation. Int. J. Chronic Obstr. Pulm. Dis. 2018,
13, 175–181. [CrossRef] [PubMed]
70. De Alencar Silva, B.S.; Gobbo, L.A.; Freire, A.P.C.F.; Trevisan, I.B.; Silva, I.G.; Ramos, E.M.C. Effects of
a resistance training with elastic tubing in strength, quality of life and dypsnea in patients with chronic
obstructive pulmonary disease. J. Phys. Educ. 2016, 27. [CrossRef]
71. De Oliveira, J.C.M.; Leitao, F.S.S.; Sampaio, L.M.M.; de Oliveira, A.C.N.; Hirata, R.P.; Costa, D.; Donner, C.F.;
de Oliveira, L.V.F. Outpatient vs. home-based pulmonary rehabilitation in COPD: A randomized controlled
trial. Multidiscip. Respir. Med. 2010, 5, 401–408. [CrossRef]
72. De Souza, Y.; da Silva, K.M.; Condesso, D.; Figueira, B.; Filho, A.J.N.; Rufino, R.; Gosselink, R.; da Costa, C.H.
Use of a home-based manual as part of a pulmonary rehabilitation program. Respir. Care 2018, 63, 1485–1491.
[CrossRef]
73. Demeyer, H.; Burtin, C.; Van Remoortel, H.; Hornikx, M.; Langer, D.; Decramer, M.; Gosselink, R.; Janssens, W.;
Troosters, T. Standardizing the Analysis of Physical Activity in Patients With COPD Following a Pulmonary
Rehabilitation Program. Chest 2014, 146, 318–327. [CrossRef] [PubMed]
74. Dourado, V.S.; Tanni, S.E.; Antunes, L.C.O.; Paiva, S.A.R.; Campana, A.O.; Renno, A.C.M.; Godoy, I. Effect of
three exercise programs on patients with chronic obstructive pulmonary disease. Braz. J. Med Biol. Res. 2009,
42, 263–271. [CrossRef] [PubMed]
75. Dourado, V.Z.; Antunes, L.C.O.; Tanni, S.E.; Godoy, I. Factors associated with the minimal clinically important
difference for health-related quality of life after physical conditioning in patients with COPD. J. Bras. De
Pneumol. 2009, 35, 846–853. [CrossRef] [PubMed]
76. Effing, T.; Zielhuis, G.; Kerstjens, H.; van der Valk, P.; van der Palen, J. Community based physiotherapeutic
exercise in COPD self-management: A randomised controlled trial. Respir. Med. 2011, 105, 418–426.
[CrossRef] [PubMed]
77. Emtner, M.; Hallin, R.; Arnardottir, R.H.; Janson, C. Effect of physical training on fat-free mass in patients with
chronic obstructive pulmonary disease (COPD). Upsala J. Med. Sci. 2015, 120, 52–58. [CrossRef] [PubMed]
78. Endo, Y.; Dobashi, K.; Uga, D.; Kato, D.; Nakazawa, R.; Sakamoto, M.; Fueki, M.; Makino, S. Effect of
12-month rehabilitation with low loading program on chronic respiratory disease. J. Phys. Ther. Sci. 2016, 28,
1032–1035. [CrossRef] [PubMed]
79. Enea, C.; Schmitt, N.; Dugú, B.; Boisseau, N.; Le Creff, C.; Denjean, A. Oxidative stress in patients with
chronic obstructive pulmonary disease after aerobic exercise training. Sci. Sports 2005, 20, 48–50. [CrossRef]
J. Clin. Med. 2019, 8, 1458 39 of 46
80. Engel, R.M.; Gonski, P.; Beath, K.; Vemulpad, S. Medium term effects of including manual therapy in
a pulmonary rehabilitation program for chronic obstructive pulmonary disease (COPD): A randomized
controlled pilot trial. J. Man. Manip. Ther. 2016, 24, 80–89. [CrossRef]
81. Etnier, J.L.; Berry, M. Fluid intelligence in an older COPD sample after short- or long-term exercise. Med. Sci.
Sports Exerc. 2001, 33, 1620–1628. [CrossRef]
82. Felcar, J.M.; Probst, V.S.; de Carvalho, D.R.; Merli, M.F.; Mesquita, R.; Vidotto, L.S.; Ribeiro, L.R.G.; Pitta, F.
Effects of exercise training in water and on land in patients with COPD: A randomised clinical trial.
Physiotherapy 2018, 104, 408–416. [CrossRef]
83. Fernandes, J.R.; da Silva, C.; da Silva, A.G.; Pinto, R.M.D.; Duarte, A.J.D.; Carvalho, C.R.; Benard, G. Effect of
an Exercise Program on Lymphocyte Proliferative Responses of COPD Patients. Lung 2018, 196, 271–276.
[CrossRef] [PubMed]
84. Fischer, M.J.; Scharloo, M.; Abbink, J.; van ’t Hul, A.; van Ranst, D.; Rudolphus, A.; Weinman, J.; Rabe, K.F.;
Kaptein, A.A. Concerns about exercise are related to walk test results in pulmonary rehabilitation for patients
with COPD. Int. J. Behav. Med. 2012, 19, 39–47. [CrossRef] [PubMed]
85. Foy, C.G.; Rejeski, W.J.; Berry, M.J.; Zaccaro, D.; Woodard, C.M. Gender moderates the effects of exercise
therapy on health-related quality of life among COPD patients. Chest 2001, 119, 70–76. [CrossRef]
86. Fuld, J.P.; Kilduff, L.P.; Neder, J.A.; Pitsiladis, Y.; Lean, M.E.J.; Ward, S.A.; Cotton, M.M. Creatine
supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax
2005, 60, 531–537. [CrossRef] [PubMed]
87. Fuller, L.M.; Button, B.; Tarrant, B.; Steward, R.; Bennett, L.; Snell, G.; Holland, A.E. Longer Versus Shorter
Duration of Supervised Rehabilitation After Lung Transplantation: A Randomized Trial. Arch. Phys. Med.
Rehabil. 2017, 98, 220–226. [CrossRef] [PubMed]
88. Gayle, R.C.; Spitler, D.L.; Karper, W.B.; Jaeger, R.M.; Rice, S.N. Psychological changes in exercising COPD
patients. Int. J. Rehabil. Res. Int. Z. Fur Rehabil. Rev. Int. De Rech. De Readapt. 1988, 11, 335–342. [CrossRef]
89. Georgiadou, O.; Vogiatzis, I.; Stratakos, G.; Koutsoukou, A.; Golemati, S.; Aliverti, A.; Roussos, C.;
Zakynthinos, S. Effects of rehabilitation on chest wall volume regulation during exercise in COPD patients.
Eur. Respir. J. 2007, 29, 284–291. [CrossRef] [PubMed]
90. Georgiopoulou, V.V.; Dimopoulos, S.; Sakellariou, D.; Papazachou, O.; Gerovasili, V.; Tasoulis, A.; Agapitou, V.;
Vogiatzis, I.; Roussos, C.; Nanas, S. Cardiopulmonary rehabilitation enhances heart rate recovery in patients
with COPD. Respir. Care 2012, 57, 2095–2103. [CrossRef]
91. Godoy, R.F.; Teixeira, P.J.; Becker Junior, B.; Michelli, M.; Godoy, D.V. Long-term repercussions of a pulmonary
rehabilitation program on the indices of anxiety, depression, quality of life and physical performance in
patients with COPD. J. Bras. De Pneumol. Publ. Da Soc. Bras. De Pneumol. E Tisilogia 2009, 35, 129–136.
92. Goldstein, R.S.; Gort, E.H.; Avendano, M.A.; Stubbing, D.; Guyatt, G.H. Randomised controlled trial of
respiratory rehabilitation. Lancet 1994, 344, 1394–1397. [CrossRef]
93. Grosbois, J.M.; Lamblin, C.; Lemaire, B.; Chekroud, H.; Dernis, J.M.; Douay, B.; Fortin, F. Long-term benefits of
exercise maintenance after outpatient rehabilitation program in patients with chronic obstructive pulmonary
disease. J. Cardiopulm. Rehabil. 1999, 19, 216–225. [CrossRef] [PubMed]
94. Guell, R.; Casan, P.; Belda, J.; Sangenis, M.; Morante, F.; Guyatt, G.H.; Sanchis, J. Long-term effects of
outpatient rehabilitation of COPD—A randomized trial. Chest 2000, 117, 976–983. [CrossRef] [PubMed]
95. Harrison, S.L.; Beauchamp, M.K.; Sibley, K.; Araujo, T.; Romano, J.; Goldstein, R.S.; Brooks, D. Minimizing
the evidence-practice gap—A prospective cohort study incorporating balance training into pulmonary
rehabilitation for individuals with chronic obstructive pulmonary disease. BMC Pulm. Med. 2015, 15, 73.
[CrossRef] [PubMed]
96. Hoogendoorn, M.; van Wetering, C.R.; Schols, A.M.; Rutten-van Molken, M.P. Is INTERdisciplinary
COMmunity-based COPD management (INTERCOM) cost-effective? Eur. Respir. J. 2010, 35, 79–87.
[CrossRef] [PubMed]
97. Houben-Wilke, S.; Janssen, D.J.A.; Franssen, F.M.E.; Vanfleteren, L.; Wouters, E.F.M.; Spruit, M.A. Contribution
of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation
on CAT scores. Health Qual. Life Outcomes 2018, 16, 205. [CrossRef] [PubMed]
98. Jacome, C.; Marques, A. Short- and Long-term Effects of Pulmonary Rehabilitation in Patients With Mild
COPD: A COMPARISON WITH PATIENTS WITH MODERATE TO SEVERE COPD. J. Cardiopulm. Rehabil.
Prev. 2016, 36, 445–453. [CrossRef]
J. Clin. Med. 2019, 8, 1458 40 of 46
99. Jácome, C.; Marques, A. Impact of pulmonary rehabilitation in subjects with mild COPD. Respir. Care 2014,
59, 1577–1582. [CrossRef]
100. Kamal, M.A.W.; Nambi, S.G.; Mahmoud, M.Z. Impact of Resisted Exercise on Chronic Obstructive Pulmonary
Disease (COPD) in Elderly Patients in Alkharj, Saudi Arabia. Int. J. Med Res. Health Sci. 2016, 5, 187–195.
101. Kanao, K.; Shiraishi, M.; Higashimoto, Y.; Maeda, K.; Sugiya, R.; Okajima, S.; Chiba, Y.; Yamagata, T.;
Terada, K.; Fukuda, K.; et al. Factors associated with the effect of pulmonary rehabilitation on physical
activity in patients with chronic obstructive pulmonary disease. Geriatr. Gerontol. Int. 2017, 17, 17–23.
[CrossRef]
102. Kavoura, P.; Kostikas, K.; Tselebis, A.; Bratis, D.; Kosmas, E.; Alchanatis, M.; Koulouris, N.G.; Bakakos, P.;
Loukides, S. Changes in BODE Quartiles After Pulmonary Rehabilitation Do Not Predict 2-Year Survival in
Patients With COPD. J. Cardiopulm. Rehabil. Prev. 2016, 36, 62–67. [CrossRef]
103. Kongsgaard, M.; Backer, V.; Jorgensen, K.; Kjaer, M.; Beyer, N. Heavy resistance training increases muscle
size, strength and physical function in elderly male COPD-patients—A pilot study. Respir. Med. 2004, 98,
1000–1007. [CrossRef] [PubMed]
104. Lan, C.C.; Chu, W.H.; Yang, M.C.; Lee, C.H.; Wu, Y.K.; Wu, C.P. Benefits of pulmonary rehabilitation in
patients with COPD and normal exercise capacity. Respir. Care 2013, 58, 1482–1488. [CrossRef] [PubMed]
105. Lan, C.C.; Huang, H.C.; Yang, M.C.; Lee, C.H.; Huang, C.Y.; Wu, Y.K. Pulmonary rehabilitation improves
subjective sleep quality in COPD. Respir. Care 2014, 59, 1569–1576. [CrossRef] [PubMed]
106. Lan, C.C.; Yang, M.C.; Huang, H.C.; Wu, C.W.; Su, W.L.; Tzeng, I.S.; Wu, Y.K. Serial changes in exercise
capacity, quality of life and cardiopulmonary responses after pulmonary rehabilitation in patients with
chronic obstructive pulmonary disease. Heart Lung J. Crit. Care 2018, 47, 477–484. [CrossRef] [PubMed]
107. Lan, C.C.; Yang, M.C.; Lee, C.H.; Huang, Y.C.; Huang, C.Y.; Huang, K.L.; Wu, Y.K. Pulmonary rehabilitation
improves exercise capacity and quality of life in underweight patients with chronic obstructive pulmonary
disease. Respirology 2011, 16, 276–283. [CrossRef] [PubMed]
108. Leite, M.R.; Ramos, E.M.; Kalva-Filho, C.A.; Freire, A.P.; de Alencar Silva, B.S.; Nicolino, J.; de
Toledo-Arruda, A.C.; Papoti, M.; Vanderlei, L.C.; Ramos, D. Effects of 12 weeks of aerobic training
on autonomic modulation, mucociliary clearance, and aerobic parameters in patients with COPD. Int. J.
Chronic Obstr. Pulm. Dis. 2015, 10, 2549–2557. [CrossRef] [PubMed]
109. López Varela, M.V.; Anido, T.; Larrosa, M. Functional status and survival in patients with chronic obstructive
pulmonary disease following pulmonary rehabilitation. Arch. De Bronconeumol. 2006, 42, 434–439. [CrossRef]
110. Lox, C.L.; Freehill, A.J. Impact of pulmonary rehabilitation on self-efficacy, quality of life, and exercise
tolerance. Rehabil. Psychol. 1999, 44, 208–221. [CrossRef]
111. Maa, S.H.; Gauthier, D.; Turner, M. Acupressure as an adjunct to a pulmonary rehabilitation program. J.
Cardiopulm. Rehabil. 1997, 17, 268–276. [CrossRef]
112. Magadle, R.; McConnell, A.K.; Beckerman, M.; Weiner, P. Inspiratory muscle training in pulmonary
rehabilitation program in COPD patients. Respir. Med. 2007, 101, 1500–1505. [CrossRef]
113. Maltais, F.; LeBlanc, P.; Jobin, J.; Berube, C.; Bruneau, J.; Carrier, L.; Breton, M.J.; Falardeau, G.; Belleau, R.
Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am.
J. Respir. Crit. Care Med. 1997, 155, 555–561. [CrossRef] [PubMed]
114. Maltais, F.; LeBlanc, P.; Simard, C.; Jobin, J.; Berube, C.; Bruneau, J.; Carrier, L.; Belleau, R. Skeletal muscle
adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit.
Care Med. 1996, 154, 442–447. [CrossRef] [PubMed]
115. Mandigout, S.; Antonini, M.T.; Laforge, Q.; Lemaire, F.; Dalmay, E.; Bouteille, B. Effects of training
rehabilitation on the physical capacity of patients suffering from chronic obstructive pulmonary disease. Sci.
Sports 2007, 22, 300–301. [CrossRef]
116. Marques, A.; Gabriel, R.; Jácome, C.; Cruz, J.; Brooks, D.; Figueiredo, D. Development of a family-based
pulmonary rehabilitation programme: An exploratory study. Disabil. Rehabil. 2015, 37, 1340–1346. [CrossRef]
[PubMed]
117. Marques, A.; Jacome, C.; Cruz, J.; Gabriel, R.; Brooks, D.; Figueiredo, D. Family-based psychosocial support
and education as part of pulmonary rehabilitation in COPD: A randomized controlled trial. Chest 2015, 147,
662–672. [CrossRef] [PubMed]
J. Clin. Med. 2019, 8, 1458 41 of 46
118. Marques, A.; Jacome, C.; Cruz, J.; Gabriel, R.; Figueiredo, D. Effects of a pulmonary rehabilitation program
with balance training on patients with COPD. J. Cardiopulm. Rehabil. Prev. 2015, 35, 154–158. [CrossRef]
[PubMed]
119. Márquez-Martín, E.; Ruiz, F.O.; Ramos, P.C.; López-Campos, J.L.; Azcona, B.V.; Cortés, E.B. Randomized
trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure
due to chronic obstructive pulmonary disease. Respir. Med. 2014, 108, 1741–1751. [CrossRef]
120. Marquis, K.; Maltais, F.; Lacasse, Y.; Lacourciere, Y.; Fortin, C.; Poirier, P. Effects of aerobic exercise training
and irbesartan on blood pressure and heart rate variability in patients with chronic obstructive pulmonary
disease. Can. Respir. J. 2008, 15, 355–360. [CrossRef]
121. Mekki, M.; Paillard, T.; Sahli, S.; Tabka, Z.; Trabelsi, Y. Effect of adding neuromuscular electrical stimulation
training to pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: Randomized
clinical trial. Clin. Rehabil. 2019, 33, 195–206. [CrossRef]
122. Milani, R.V.; Lavie, C.J. Disparate effects of out-patient cardiac and pulmonary rehabilitation programs on
work efficiency and peak aerobic capacity in patients with coronary disease or severe obstructive pulmonary
disease. J. Cardiopulm. Rehabil. 1998, 18, 17–22. [CrossRef]
123. Mkacher, W.; Mekki, M.; Tabka, Z.; Trabelsi, Y. Effect of 6 Months of Balance Training During Pulmonary
Rehabilitation in Patients With COPD. J. Cardiopulm. Rehabil. Prev. 2015, 35, 207–213. [CrossRef]
124. Moezy, A.; Erfani, A.; Mazaherinezhad, A.; Mousavi, S.A.J. Downhill walking influence on physical condition
and quality of life in patients with COPD: A randomized controlled trial. Med. J. Islam. Repub. Iran 2018, 32,
49. [CrossRef]
125. Neunhauserer, D.; Steidle-Kloc, E.; Weiss, G.; Kaiser, B.; Niederseer, D.; Hartl, S.; Tschentscher, M.; Egger, A.;
Schonfelder, M.; Lamprecht, B.; et al. Supplemental Oxygen During High-Intensity Exercise Training in
Nonhypoxemic Chronic Obstructive Pulmonary Disease. Am. J. Med. 2016, 129, 1185–1193. [CrossRef]
126. Ortega, F.; Toral, J.; Cejudo, P.; Villagomez, R.; Sanchez, H.; Castillo, J.; Montemayor, T. Comparison of effects
of strength and endurance training in patients with chronic obstructive pulmonary disease. Am. J. Respir.
Crit. Care Med. 2002, 166, 669–674. [CrossRef]
127. Osadnik, C.R.; Loeckx, M.; Louvaris, Z.; Demeyer, H.; Langer, D.; Rodrigues, F.M.; Janssens, W.; Vogiatzis, I.;
Troosters, T. The likelihood of improving physical activity after pulmonary rehabilitation is increased in
patients with COPD who have better exercise tolerance. Int. J. Chronic Obstr. Pulm. Dis. 2018, 13, 3515–3527.
[CrossRef]
128. Panton, L.B.; Golden, J.; Broeder, C.E.; Browder, K.D.; Cestaro-Seifer, D.J.; Seifer, F.D. The effects of resistance
training on functional outcomes in patients with chronic obstructive pulmonary disease. Eur. J. Appl. Physiol.
2004, 91, 443–449. [CrossRef]
129. Papp, M.E.; Wändell, P.E.; Lindfors, P.; Nygren-Bonnier, M. Effects of yogic exercises on functional capacity,
lung function and quality of life in participants with obstructive pulmonary disease: A randomized controlled
study. Eur. J. Phys. Rehabil. Med. 2017, 53, 447–461.
130. Pereira, E.D.B.; Viana, C.S.; Taunay, T.C.E.; Sales, P.U.; Lima, J.W.O.; Holanda, M.A. Improvement of Cognitive
Function After a Three-Month Pulmonary Rehabilitation Program for COPD Patients. Lung 2011, 189,
279–285. [CrossRef]
131. Pitta, F.; Troosters, T.; Probst, V.S.; Langer, D.; Decramer, M.; Gosselink, R. Are patients with COPD more
active after pulmonary rehabilitation? Chest 2008, 134, 273–280. [CrossRef]
132. Polkey, M.I.; Qiu, Z.H.; Zhou, L.; Zhu, M.D.; Wu, Y.X.; Chen, Y.Y.; Ye, S.P.; He, Y.S.; Jiang, M.; He, B.T.; et al.
Tai Chi and Pulmonary Rehabilitation Compared for Treatment-Naive Patients With COPD: A Randomized
Controlled Trial. Chest 2018, 153, 1116–1124. [CrossRef]
133. Probst, V.S.; Kovelis, D.; Hernandes, N.A.; Camillo, C.A.; Cavalheri, V.; Pitta, F. Effects of 2 exercise training
programs on physical activity in daily life in patients with COPD. Respir. Care 2011, 56, 1799–1807. [CrossRef]
134. Probst, V.S.; Troosters, T.; Pitta, F.; Decramer, M.; Gosselink, R. Cardiopulmonary stress during exercise
training in patients with COPD. Eur. Respir. J. 2006, 27, 1110–1118. [CrossRef]
135. Radom-Aizik, S.; Kaminski, N.; Hayek, S.; Halkin, H.; Cooper, D.M.; Ben-Dov, I. Effects of exercise training
on quadriceps muscle gene expression in chronic obstructive pulmonary disease. J. Appl. Physiol. 2007, 102,
1976–1984. [CrossRef]
J. Clin. Med. 2019, 8, 1458 42 of 46
136. Rejbi, I.B.; Trabelsi, Y.; Chouchene, A.; Ben Turkia, W.; Ben Saad, H.; Zbidi, A.; Kerken, A.; Tabka, Z. Changes
in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy
subjects. Int. J. Chronic Obstr. Pulm. Dis. 2010, 5, 209–215. [CrossRef]
137. Rinaldo, N.; Bacchi, E.; Coratella, G.; Vitali, F.; Milanese, C.; Rossi, A.; Schena, F.; Lanza, M. Effects of
Combined Aerobic-Strength Training vs Fitness Education Program in COPD Patients. Int. J. Sports Med.
2017, 38, 1001–1008. [CrossRef]
138. Rizk, A.K.; Wardini, R.; Chan-Thim, E.; Bacon, S.L.; Lavoie, K.L.; Pepin, V. Acute responses to exercise
training and relationship with exercise adherence in moderate chronic obstructive pulmonary disease. Chron.
Respir. Dis. 2015, 12, 329–339. [CrossRef]
139. Roman, M.; Larraz, C.; Gomez, A.; Ripoll, J.; Mir, I.; Miranda, E.Z.; Macho, A.; Thomas, V.; Esteva, M.
Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: A
randomized controlled trial. BMC Fam. Pract. 2013, 14, 21. [CrossRef]
140. Santana, V.T.S.; Squassoni, S.D.; Neder, J.A.; Fiss, E. Influence of current smoking on adherence and responses
to pulmonary rehabilitation in patients with COPD. Braz. J. Phys. Ther. 2010, 14, 16–23. [CrossRef]
141. Scherer, Y.K.; Schmieder, L.E. The effect of a pulmonary rehabilitation program on self-efficacy, perception of
dyspnea, and physical endurance. Heart Lung J. Crit. Care 1997, 26, 15–22. [CrossRef]
142. Scherer, Y.K.; Schmieder, L.E.; Shimmel, S. The effects of education alone and in combination with pulmonary
rehabilitation on self-efficacy in patients with COPD. Rehabil. Nurs. Off. J. Assoc. Rehabil. Nurses 1998, 23,
71–77. [CrossRef]
143. Sciriha, A.; Lungaro-Mifsud, S.; Bonello, A.; Agius, T.; Scerri, J.; Ellul, B.; Fenech, A.; Camilleri, L.; Montefort, S.
Systemic inflammation in COPD is not influenced by pulmonary rehabilitation. Eur. J. Physiother. 2017, 19,
194–200. [CrossRef]
144. Sciriha, A.; Lungaro-Mifsud, S.; Scerri, J.; Bilocca, D.; Fsadni, C.; Fsadni, P.; Gerada, E.; Gouder, C.;
Camilleri, L.; Montefort, S. Pulmonary rehabilitation in chronic obstructive pulmonary disease: Outcomes in
a 12 week programme. Eur. J. Physiother. 2015, 17, 215–223. [CrossRef]
145. Sciriha, A.; Lungaro-Mifsud, S.; Scerri, J.; Magro, R.; Camilleri, L.; Montefort, S. Health status of COPD
patients undergoing pulmonary rehabilitation: A comparative responsiveness of the CAT and SGRQ. Chron.
Respir. Dis. 2017, 14, 352–359. [CrossRef]
146. Silva, B.S.A.; Lira, F.S.; Rossi, F.E.; Ramos, D.; Uzeloto, J.S.; Freire, A.; de Lima, F.F.; Gobbo, L.A.; Ramos, E.M.C.
Inflammatory and Metabolic Responses to Different Resistance Training on Chronic Obstructive Pulmonary
Disease: A Randomized Control Trial. Front. Physiol. 2018, 9, 262. [CrossRef]
147. Silva, B.S.A.; Ramos, D.; Bertolini, G.N.; Freire, A.; Leite, M.R.; Camillo, C.A.; Gobbo, L.A.; Ramos, E.M.C.
Resistance exercise training improves mucociliary clearance in subjects with COPD: A randomized clinical
trial. Pulmonology 2019. [CrossRef]
148. Skumlien, S.; Aure Skogedal, E.; Skrede Ryg, M.; Bjortuft, O. Endurance or resistance training in primary
care after in-patient rehabilitation for COPD? Respir. Med. 2008, 102, 422–429. [CrossRef]
149. Solanes, I.; Guell, R.; Casan, P.; Sotomayor, C.; Gonzalez, A.; Feixas, T.; Gonzalez, M.; Guyatt, G. Duration of
pulmonary rehabilitation to achieve a plateau in quality of life and walk test in COPD. Respir. Med. 2009, 103,
722–728. [CrossRef]
150. Spencer, L.M.; Alison, J.A.; McKeough, Z.J. A Survey of Opinions and Attitudes Toward Exercise Following
a 12-month Maintenance Exercise Program for People with COPD. Cardiopulm. Phys. Ther. J. 2013, 24, 30–35.
[CrossRef]
151. Spielmanns, M.; Fuchs-Bergsma, C.; Winkler, A.; Fox, G.; Krüger, S.; Baum, K. Effects of oxygen supply during
training on subjects with COPD who are normoxemic at rest and during exercise: A blinded randomized
controlled trial. Respir. Care 2015, 60, 540–548. [CrossRef]
152. Spruit, M.A.; Gosselink, R.; Troosters, T.; De Paepe, K.; Decramer, M. Resistance versus endurance training in
patients with COPD and peripheral muscle weakness. Eur. Respir. J. 2002, 19, 1072–1078. [CrossRef]
153. Spruit, M.A.; Gosselink, R.; Troosters, T.; Kasran, A.; Van Vliet, M.; Decramer, M. Low-grade systemic
inflammation and the response to exercise training in patients with advanced COPD. Chest 2005, 128,
3183–3190. [CrossRef]
154. Stav, D.; Raz, M.; Shpirer, I. Three years of pulmonary rehabilitation: Inhibit the decline in airflow obstruction,
improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease. BMC
Pulm. Med. 2009, 9, 26. [CrossRef]
J. Clin. Med. 2019, 8, 1458 43 of 46
155. Steinsbekk, A.; Lomundal, B.K. Three-year follow-up after a two-year comprehensive pulmonary
rehabilitation program. Chron. Respir. Dis. 2009, 6, 5–11. [CrossRef]
156. Strijbos, J.H.; Postma, D.S.; van Altena, R.; Gimeno, F.; Koeter, G.H. Feasibility and effects of a home-care
rehabilitation program in patients with chronic obstructive pulmonary disease. J. Cardiopulm. Rehabil. 1996,
16, 386–393. [CrossRef]
157. Strijbos, J.H.; Postma, D.S.; vanAltena, R.; Gimeno, F.; Koeter, G.H. A comparison between an outpatient
hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in
patients with COPD - A follow-up of 18 months. Chest 1996, 109, 366–372. [CrossRef]
158. Theander, K.; Jakobsson, P.; Jorgensen, N.; Unosson, M. Effects of pulmonary rehabilitation on fatigue,
functional status and health perceptions in patients with chronic obstructive pulmonary disease: A
randomized controlled trial. Clin. Rehabil. 2009, 23, 125–136. [CrossRef]
159. Theodorakopoulou, E.P.; Gennimata, S.A.; Harikiopoulou, M.; Kaltsakas, G.; Palamidas, A.; Koutsoukou, A.;
Roussos, C.; Kosmas, E.N.; Bakakos, P.; Koulouris, N.G. Effect of pulmonary rehabilitation on tidal expiratory
flow limitation at rest and during exercise in COPD patients. Respir. Physiol. Neurobiol. 2017, 238, 47–54.
[CrossRef]
160. Toledo, A.; Borghi-Silva, A.; Sampaio, L.M.; Ribeiro, K.P.; Baldissera, V.; Costa, D. The impact of noninvasive
ventilation during the physical training in patients with moderate-to-severe chronic obstructive pulmonary
disease (COPD). Clinics 2007, 62, 113–120. [CrossRef]
161. Trappenburg, J.C.; Troosters, T.; Spruit, M.A.; Vandebrouck, N.; Decramer, M.; Gosselink, R. Psychosocial
conditions do not affect short-term outcome of multidisciplinary rehabilitation in chronic obstructive
pulmonary disease. Arch. Phys. Med. Rehabil. 2005, 86, 1788–1792. [CrossRef]
162. Troosters, T.; Gosselink, R.; Decramer, M. Short- and long-term effects of outpatient rehabilitation in patients
with chronic obstructive pulmonary disease: A randomized trial. Am. J. Med. 2000, 109, 207–212. [CrossRef]
163. Troosters, T.; Gosselink, R.; Decramer, M. Exercise training in COPD: How to distinguish responders from
nonresponders. J. Cardiopulm. Rehabil. 2001, 21, 10–17. [CrossRef]
164. Tselebis, A.; Bratis, D.; Pachi, A.; Moussas, G.; Ilias, I.; Harikiopoulou, M.; Theodorakopoulou, E.; Dumitru, S.;
Kosmas, E.; Vgontzas, A.; et al. A pulmonary rehabilitation program reduces levels of anxiety and depression
in COPD patients. Multidiscip. Respir. Med. 2013, 8. [CrossRef]
165. Van de Bool, C.; Rutten, E.P.A.; van Helvoort, A.; Franssen, F.M.E.; Wouters, E.F.M.; Schols, A. A randomized
clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J. Cachexia
Sarcopenia Muscle 2017, 8, 748–758. [CrossRef]
166. Van Helvoort, H.A.; de Boer, R.C.; van de Broek, L.; Dekhuijzen, R.; Heijdra, Y.F. Exercises commonly used
in rehabilitation of patients with chronic obstructive pulmonary disease: Cardiopulmonary responses and
effect over time. Arch. Phys. Med. Rehabil. 2011, 92, 111–117. [CrossRef]
167. Vasilopoulou, M.; Papaioannou, A.I.; Kaltsakas, G.; Louvaris, Z.; Chynkiamis, N.; Spetsioti, S.; Kortianou, E.;
Genimata, S.A.; Palamidas, A.; Kostikas, K.; et al. Home-based maintenance tele-rehabilitation reduces the
risk for acute exacerbations of COPD, hospitalisations and emergency department visits. Eur. Respir. J. 2017,
49. [CrossRef]
168. Voduc, N.; Tessier, C.; Sabri, E.; Fergusson, D.; Lavallee, L.; Aaron, S.D. Effects of oxygen on exercise duration
in chronic obstructive pulmonary disease patients before and after pulmonary rehabilitation. Can. Respir. J.
2010, 17, e14–e19. [CrossRef]
169. Vogiatzis, I.; Nanas, S.; Roussos, C. Interval training as an alternative modality to continuous exercise in
patients with COPD. Eur. Respir. J. 2002, 20, 12–19. [CrossRef]
170. Vogiatzis, I.; Williamson, A.F.; Miles, J.; Taylor, I.K. Physiological response to moderate exercise workloads in
a pulmonary rehabilitation program in patients with varying degrees of airflow obstruction. Chest 1999, 116,
1200–1207. [CrossRef]
171. Vonbank, K.; Strasser, B.; Mondrzyk, J.; Marzluf, B.A.; Richter, B.; Losch, S.; Nell, H.; Petkov, V.; Haber, P.
Strength training increases maximum working capacity in patients with COPD - Randomized clinical trial
comparing three training modalities. Respir. Med. 2012, 106, 557–563. [CrossRef]
172. Wada, J.T.; Borges-Santos, E.; Porras, D.C.; Paisani, D.M.; Cukier, A.; Lunardi, A.C.; Carvalho, C.R. Effects
of aerobic training combined with respiratory muscle stretching on the functional exercise capacity and
thoracoabdominal kinematics in patients with COPD: A randomized and controlled trial. Int. J. Chronic
Obstr. Pulm. Dis. 2016, 11, 2691–2700. [CrossRef]
J. Clin. Med. 2019, 8, 1458 44 of 46
173. Wadell, K.; Henriksson-Larsen, K.; Lundgren, R.; Sundelin, G. Group training in patients with
COPD—Long-term effects after decreased training frequency. Disabil. Rehabil. 2005, 27, 571–581. [CrossRef]
[PubMed]
174. Wadell, K.; Sundelin, G.; Henriksson-Larsen, K.; Lundgren, R. High intensity physical group training in
water—An effective training modality for patients with COPD. Respir. Med. 2004, 98, 428–438. [CrossRef]
[PubMed]
175. Weiner, P.; Azgad, Y.; Ganam, R. Inspiratory muscle training combined with general exercise reconditioning
in patients with COPD. Chest 1992, 102, 1351–1356. [CrossRef] [PubMed]
176. Wijkstra, P.J.; Van Altena, R.; Kraan, J.; Otten, V.; Postma, D.S.; Koeter, G.H. Quality of life in patients with
chronic obstructive pulmonary disease improves after rehabilitation at home. Eur. Respir. J. 1994, 7, 269–273.
[CrossRef] [PubMed]
177. Wijkstra, P.J.; van der Mark, T.W.; Kraan, J.; van Altena, R.; Koeter, G.H.; Postma, D.S. Effects of home
rehabilitation on physical performance in patients with chronic obstructive pulmonary disease (COPD). Eur.
Respir. J. 1996, 9, 104–110. [CrossRef] [PubMed]
178. Wright, P.R.; Heck, H.; Langenkamp, H. Effects of a resistance training on pulmonary function and
performance measurements in patients with chronic obstructive pulmonary disease. Eur. J. Sport Sci. 2003, 3,
1–10. [CrossRef]
179. Wu, W.; Liu, X.; Liu, J.; Li, P.; Wang, Z. Effectiveness of water-based Liuzijue exercise on respiratory muscle
strength and peripheral skeletal muscle function in patients with COPD. Int. J. Chronic Obstr. Pulm. Dis.
2018, 13, 1713–1726. [CrossRef]
180. Xu, J.; He, S.; Han, Y.; Pan, J.; Cao, L. Effects of modified pulmonary rehabilitation on patients with moderate
to severe chronic obstructive pulmonary disease: A randomized controlled trail. Int. J. Nurs. Sci. 2017, 4,
219–224. [CrossRef]
181. Zambom-Ferraresi, F.; Cebollero, P.; Gorostiaga, E.M.; Hernandez, M.; Hueto, J.; Cascante, J.; Rezusta, L.;
Val, L.; Anton, M.M. Effects of Combined Resistance and Endurance Training Versus Resistance Training
Alone on Strength, Exercise Capacity, and Quality of Life in Patients With COPD. J. Cardiopulm. Rehabil. Prev.
2015, 35, 446–453. [CrossRef]
182. ZuWallack, R.; Hashim, A.; McCusker, C.; Normandin, E.; Benoit-Connors, M.L.; Lahiri, B. The trajectory of
change over multiple outcome areas during comprehensive outpatient pulmonary rehabilitation. Chron.
Respir. Dis. 2006, 3, 11–18. [CrossRef]
183. Zwerink, M.; Effing, T.; Kerstjens, H.A.; van der Valk, P.; Brusse-Keizer, M.; Zielhuis, G.; van der Palen, J.
Cost-Effectiveness of a Community-Based Exercise Programme in COPD Self-Management. COPD 2016, 13,
214–223. [CrossRef] [PubMed]
184. Zwerink, M.; van der Palen, J.; Kerstjens, H.A.; van der Valk, P.; Brusse-Keizer, M.; Zielhuis, G.; Effing, T. A
community-based exercise programme in COPD self-management: Two years follow-up of the COPE-II
study. Respir. Med. 2014, 108, 1481–1490. [CrossRef] [PubMed]
185. Verrill, D.E.; Barton, C.; Beasley, W.; Lippard, W.M. The effects of short-term and long-term pulmonary
rehabilitation on functional capacity, perceived dyspnea, and quality of life. Chest 2005, 128, 673–683.
[CrossRef] [PubMed]
186. Abd El-Kader, S.M.; Al-Jiffri, O.H.; Ashmawy, E.M.; Gaowgzeh, R.A. Treadmill walking exercise modulates
bone mineral status and inflammatory cytokines in obese asthmatic patients with long term intake of
corticosteroids. Afr. Health Sci. 2016, 16, 798–808. [CrossRef] [PubMed]
187. Arandelovic, M.; Stankovic, I.; Nikolic, M. Swimming and persons with mild persistant asthma. Sci. World J.
2007, 7, 1182–1188. [CrossRef]
188. Boyd, A.; Yang, C.T.; Estell, K.; Ms, C.T.; Gerald, L.B.; Dransfield, M.; Bamman, M.; Bonner, J.; Atkinson, T.P.;
Schwiebert, L.M. Feasibility of exercising adults with asthma: A randomized pilot study. Allergy Asthma
Clin. Immunol. Off. J. Can. Soc. Allergy Clin. Immunol. 2012, 8, 13. [CrossRef] [PubMed]
189. Cochrane, L.M.; Clark, C.J. Benefits and problems of a physical training programme for asthmatic patients.
Thorax 1990, 45, 345–351. [CrossRef]
J. Clin. Med. 2019, 8, 1458 45 of 46
190. Dogra, S.; Kuk, J.L.; Baker, J.; Jamnik, V. Exercise is associated with improved asthma control in adults.
Eur. Respir. J. 2011, 37, 318–323. [CrossRef]
191. Franca-Pinto, A.; Mendes, F.A.; de Carvalho-Pinto, R.M.; Agondi, R.C.; Cukier, A.; Stelmach, R.;
Saraiva-Romanholo, B.M.; Kalil, J.; Martins, M.A.; Giavina-Bianchi, P.; et al. Aerobic training decreases
bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: A
randomised controlled trial. Thorax 2015, 70, 732–739. [CrossRef]
192. Goncalves, R.C.; Nunes, M.P.T.; Cukier, A.; Stelmach, R.; Martins, M.A.; Carvalho, C.R.F. Effects of an aerobic
physical training program on psychosocial characteristics, quality-of-life, symptoms and exhaled nitric oxide
in individuals with moderate or severe persistent asthma. Braz. J. Phys. Ther. 2008, 12, 127–135.
193. Haas, F.; Pasierski, S.; Levine, N.; Bishop, M.; Axen, K.; Pineda, H.; Haas, A. Effect of aerobic training on
forced expiratory airflow in exercising asthmatic humans. J. Appl. Physiol. 1987, 63, 1230–1235. [CrossRef]
[PubMed]
194. Mendes, F.A.; Almeida, F.M.; Cukier, A.; Stelmach, R.; Jacob-Filho, W.; Martins, M.A.; Carvalho, C.R. Effects
of aerobic training on airway inflammation in asthmatic patients. Med. Sci. Sports Exerc. 2011, 43, 197–203.
[CrossRef] [PubMed]
195. Mendes, F.A.R.; Goncalves, R.C.; Nunes, M.P.T.; Saraiva-Romanholo, B.M.; Cukier, A.; Stelmach, R.;
Jacob-Filho, W.; Martins, M.A.; Carvalho, C.R.F. Effects of Aerobic Training on Psychosocial Morbidity and
Symptoms in Patients With Asthma A Randomized Clinical Trial. Chest 2010, 138, 331–337. [CrossRef]
[PubMed]
196. Bostrom, C.; Elfving, B.; Dupre, B.; Opava, C.H.; Lundberg, I.E.; Jansson, E. Effects of a one-year physical
activity programme for women with systemic lupus erythematosus—A randomized controlled study. Lupus
2016, 25, 602–616. [CrossRef] [PubMed]
197. Florian, J.; Rubin, A.; Mattiello, R.; da Fontoura, F.F.; Camargo, J.D.P.; Teixeira, P.J.Z. Impact of pulmonary
rehabilitation on quality of life and functional capacity in patients on waiting lists for lung transplantation. J.
Bras. De Pneumol. 2013, 39, 349–356. [CrossRef] [PubMed]
198. Gaunaurd, I.A.; Gomez-Marin, O.W.; Ramos, C.F.; Sol, C.M.; Cohen, M.I.; Cahalin, L.P.; Cardenas, D.D.;
Jackson, R.M. Physical activity and quality of life improvements of patients with idiopathic pulmonary
fibrosis completing a pulmonary rehabilitation program. Respir. Care 2014, 59, 1872–1879. [CrossRef]
[PubMed]
199. Igarashi, A.; Iwanami, Y.; Sugino, K.; Gocho, K.; Homma, S.; Ebihara, S. Using 6-Min Walk Distance Expressed
as a Percentage of Reference to Evaluate the Effect of Pulmonary Rehabilitation in Elderly Patients With
Interstitial Lung Disease. J. Cardiopulm. Rehabil. Prev. 2018, 38, 342–347. [CrossRef]
200. Jackson, R.M.; Gómez-Marín, O.W.; Ramos, C.F.; Sol, C.M.; Cohen, M.I.; Gaunaurd, I.A.; Cahalin, L.P.;
Cardenas, D.D. Exercise limitation in IPF patients: A randomized trial of pulmonary rehabilitation. Lung
2014, 192, 367–376. [CrossRef]
201. Marcellis, R.; Van der Veeke, M.; Mesters, I.; Drent, M.; De Bie, R.; De Vries, G.; Lenssen, A. Does physical
training reduce fatigue in sarcoidosis? Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. Wasog 2015, 32, 53–62.
202. Naz, I.; Ozalevli, S.; Ozkan, S.; Sahin, H. Efficacy of a Structured Exercise Program for Improving Functional
Capacity and Quality of Life in Patients With Stage 3 and 4 Sarcoidosis: A RANDOMIZED CONTROLLED
TRIAL. J. Cardiopulm. Rehabil. Prev. 2018, 38, 124–130. [CrossRef]
203. Naz, I.; Sahin, H.; Uçsular, F.D.; Yalniz, E. A comparison trial of eight weeks versus twelve weeks of exercise
program in interstitial lung diseases. Sarcoidosis Vasc. Diffus. Lung Dis. 2018, 35, 299–307.
204. Perez-Bogerd, S.; Wuyts, W.; Barbier, V.; Demeyer, H.; Van Muylem, A.; Janssens, W.; Troosters, T. Short and
long-term effects of pulmonary rehabilitation in interstitial lung diseases: A randomised controlled trial.
Respir. Res. 2018, 19, 182. [CrossRef]
205. Sciriha, A.; Lungaro-Mifsud, S.; Fsadni, P.; Scerri, J.; Montefort, S. Pulmonary Rehabilitation in patients with
Interstitial Lung Disease: The effects of a 12-week programme. Respir. Med. 2019, 146, 49–56. [CrossRef]
[PubMed]
206. Strookappe, B.; Elfferich, M.; Swigris, J.; Verschoof, A.; Veschakelen, J.; Knevel, T.; Drent, M. Benefits of
physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: A pilot
study. Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG 2015, 32, 43–52.
J. Clin. Med. 2019, 8, 1458 46 of 46
207. Vainshelboim, B.; Kramer, M.R.; Fox, B.D.; Izhakian, S.; Sagie, A.; Oliveira, J. Supervised exercise training
improves exercise cardiovascular function in idiopathic pulmonary fibrosis. Eur. J. Phys. Rehabil. Med. 2017,
53, 209–218. [PubMed]
208. Vainshelboim, B.; Oliveira, J.; Fox, B.D.; Soreck, Y.; Fruchter, O.; Kramer, M.R. Long-term effects of a 12-week
exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung 2015, 193, 345–354.
[CrossRef] [PubMed]
209. Vainshelboim, B.; Oliveira, J.; Yehoshua, L.; Weiss, I.; Fox, B.D.; Fruchter, O.; Kramer, M.R. Exercise
training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis.
Respir. Int. Rev. Thorac. Dis. 2014, 88, 378–388. [CrossRef] [PubMed]
210. Cazzola, M.; Calzetta, L.; Bettoncelli, G.; Novelli, L.; Cricelli, C.; Rogliani, P. Asthma and comorbid medical
illness. Eur. Respir. J. 2011, 38, 42–49. [CrossRef] [PubMed]
211. King, C.S.; Nathan, S.D. Idiopathic pulmonary fibrosis: Effects and optimal management of comorbidities.
Lancet Respir. Med. 2017, 5, 72–84. [CrossRef]
212. Fabbri, L.M.; Boyd, C.; Boschetto, P.; Rabe, K.F.; Buist, A.S.; Yawn, B.; Leff, B.; Kent, D.M.; Schünemann, H.J.
How to integrate multiple comorbidities in guideline development: Article 10 in integrating and coordinating
efforts in COPD guideline development. An official ATS/ERS workshop report. Proc. Am. Thorac. Soc. 2012,
9, 274–281. [CrossRef]
213. Schulz, K.F.; Altman, D.G.; Moher, D. CONSORT 2010 statement: Updated guidelines for reporting parallel
group randomised trials. BMC Med. 2010, 8, 18. [CrossRef] [PubMed]
214. Hsu, C.-Y.; Hsieh, P.-L.; Hsiao, S.-F.; Chien, M.-Y. Effects of exercise training on autonomic function in chronic
heart failure: Systematic review. Biomed Res. Int. 2015, 2015, 8. [CrossRef] [PubMed]
215. Cornelis, N.; Nassen, J.; Buys, R.; Fourneau, I.; Cornelissen, V. The Impact of Supervised Exercise Training on
Traditional Cardiovascular Risk Factors in Patients With Intermittent Claudication: A Systematic Review
and Meta-Analysis. Eur. J. Vasc. Endovasc. Surg. 2019, 58, 75–87. [CrossRef] [PubMed]
216. Kachur, S.; Chongthammakun, V.; Lavie, C.J.; De Schutter, A.; Arena, R.; Milani, R.V.; Franklin, B.A. Impact
of cardiac rehabilitation and exercise training programs in coronary heart disease. Prog. Cardiovasc. Dis.
2017, 60, 103–114. [CrossRef] [PubMed]
217. Lavie, C.J.; Arena, R.; Swift, D.L.; Johannsen, N.M.; Sui, X.; Lee, D.-c.; Earnest, C.P.; Church, T.S.; O’Keefe, J.H.;
Milani, R.V. Exercise and the cardiovascular system: Clinical science and cardiovascular outcomes. Circ. Res.
2015, 117, 207–219. [CrossRef]
218. Hansen, D.; Dendale, P.; Coninx, K.; Vanhees, L.; Piepoli, M.F.; Niebauer, J.; Cornelissen, V.; Pedretti, R.;
Geurts, E.; Ruiz, G.R. The European Association of Preventive Cardiology Exercise Prescription in Everyday
Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for
optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology.
Eur. J. Prev. Cardiol. 2017, 24, 1017–1031. [PubMed]
219. American Association of Cardiovascular Pulmonary Rehabilitation. Guidelines for Pulmonary Rehabilitation
Programs; Human Kinetics: Stanningley, UK, 2011.
220. Troosters, T.; Van Remoortel, H. Pulmonary rehabilitation and cardiovascular disease. Semin. Respir. Crit.
Care Med. 2009, 30, 675–683. [CrossRef]
221. Hansen, D.; Piepoli, M.F.; Doehner, W. The importance of rehabilitation in the secondary prevention of
cardiovascular disease. Eur. J. Prev. Cardiol. 2019, 26, 273–276. [CrossRef]
222. American College of Sports Medicine. ACSM’s Guidelines for Exercise Testing and Prescription; Lippincott
Williams & Wilkins: Philadelphia, PA, USA, 2013.
223. Piepoli, M.F.; Corra, U.; Benzer, W.; Bjarnason-Wehrens, B.; Dendale, P.; Gaita, D.; McGee, H.; Mendes, M.;
Niebauer, J.; Zwisler, A.-D.O. Secondary prevention through cardiac rehabilitation: From knowledge to
implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of
Cardiovascular Prevention and Rehabilitation. Eur. J. Cardiovasc. Prev. Rehabil. 2010, 17, 1–17. [CrossRef]
224. Wenger, N.K. Current status of cardiac rehabilitation. J. Am. Coll. Cardiol. 2008, 51, 1619–1631. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
